Severe malnutrition, growth and zinc supplementation. by Doherty, C.
Severe malnutrition, growth and zinc supplementation
A thesis submitted for the degree of Doctor of Medicine in the University of London 
by
Dr Conor Doherty MB BS MRCP (UK)
Department of Child Health, University of Glasgow, The Royal Hospital for Sick 
Children, Glasgow.
The work in this thesis is based on research carried out whilst a research fellow at the 
Department of Child Life & Health, University of Edinburgh, Scotland.
June 2004
UMI Number: U602735
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
Dissertation Publishing
UMI U602735
Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author.
Microform Edition © ProQuest LLC.
All rights reserved. This work is protected against 
unauthorized copying under Title 17, United States Code.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
Dedication
For my parents
Abstract
Aims
To describe early linear and ponderal growth, collagen turnover, bone osteoblastic 
activity and growth, and insulin like growth factor (IGF) axis activity during 
rehabilitation of severely malnourished children and compare the effect of 3 regimens 
of zinc supplementation.
Methods
141 children were randomised in a double blind trial to either regimen 1: 1.5 
mg/kg/day (mg of elemental zinc per kg body weight of zinc sulphate) for 15 days 
followed by placebo for 15 days, or regimen 2: 6.0mg/kg/day for 15 days followed by 
placebo for 15 days, or regimen 3: 6.0mg/kg/day for 30 days. Markers of collagen 
formation (serum pro-collagen type 1 c terminal propeptide (PICP), and type 3 n 
terminal propeptide (P3NP)) and degradation (plasma cross-linked telopeptide of type 
1 collagen (1CTP)), osteoblastic activity (bone alkaline phosphatase (BAP)), IGF1 
and insulin like growth factor binding proteins 2 & 3 (IGFBP2 and IGFBP3) were 
assessed.
Results
There were no significant differences between zinc regimens in anthropometric or 
biochemical marker change. Mortality was significantly increased in children who 
received high dose zinc (6.0mg/kg) initially (Yates corrected chi-square p value of
0.033). Linear growth was significantly associated with initial weight-for-height Z 
score (WHZ). Plasma IGF-I, IGFBP-3, PICP, P3NP and BAP were low and increased 
whilst IGFBP-2 and ICTP were increased and fell during refeeding (P <0.001).
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IGFBP2 correlated positively with ICTP and negatively with PICP, BAP, IGF1 and 
IGFBP3 (p<0.01). Ponderal growth correlated with increases in IGF-I, IGFBP-3, 
PICP, P3NP and BAP over 30 days (P <0.01). Linear growth over 90 days correlated 
with increases of IGFBP-3 (P<0.05), PICP (P <0.01) and P3NP (P <0.01).
Conclusions
Alterations in the Growth Hormone /IGF axis in response to diet may control the 
coupling of bone resorption to formation and collagen deposition. There is no benefit 
in using higher dose zinc regimens and they might contribute to increased mortality.
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Chapter 1: Introduction
Rehabilitation from severe protein energy malnutrition and optimal catch-up growth 
require the provision of adequate macro and micro-nutrients. The ideal diet has long 
been the subject of debate, and there has been much discussion of the importance of 
micronutrients. Zinc deficiency has been implicated as a limiting factor in recovery 
(Hambidge 1997). Currently there exists no reliable test for detecting zinc deficiency, 
particularly in the presence of co-existing protein-energy malnutrition, other than 
empirically, by detecting a positive response to supplemental zinc.
Linear growth retardation is common in developing countries and has a multi-factorial 
origin. Zinc deficiency in particular has been increasingly implicated. However zinc 
supplementation of growth-retarded and presumed zinc-deficient children have had 
mixed effects on the promotion of linear catch-up growth (Bates 1993; Gibson 1989; 
Hambidge 1985; Nguyen 1996; Rosado 1997; Walravens 1989). This probably 
reflects both the diversity of populations in which zinc supplementation was 
employed in terms of age, degrees of growth retardation, dietary intake, availability of 
zinc and other growth limiting factors, as well as study design.
Zinc supplementation trials in children recovering from severe protein-energy 
malnutrition have demonstrated benefits in terms of ponderal growth (Golden 1981) 
and immunity (Schlesinger 1992). The process of linear growth and its relationship to 
ponderal growth is not well understood. In one of the few studies that has looked at 
this in the early phase of rehabilitation from severe malnutrition Walker et al looked 
at catch-up growth retrospectively in a group of 369 malnourished hospitalised 
children and assessed influences on linear growth (Walker 1988). Their group as a
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whole did not demonstrate linear catch up but a subgroup, who were more stunted 
initially, did. Two-thirds of the group grew linearly only when they had attained 85% 
weight for length and they speculated that the diets were limiting in one or more 
nutrients essential for linear growth such as zinc. Further studies have demonstrated 
that zinc promotes deposition of lean tissue in this period and could thus influence 
linear growth (Golden 1992).
To clarify these conflicting studies I designed a randomised, double blind, 
intervention study of the effect of three regimens of oral zinc supplementation on the 
recovery of severely malnourished children admitted to an in-patient nutritional 
rehabilitation unit, focusing on anthropometric and knemometric outcomes and 
biochemical markers of collagen and bone turnover and growth hormone axis activity.
1.1 Objectives
1. To describe the patterns of and relationship between ponderal and linear catch-up 
growth in the recovery phase from severe malnutrition
2. To describe bone, soft tissue and collagen turnover during this phase
3. To assess the effects of three different regimens of zinc supplementation on the 
above processes and thus the optimal dosage range for severely malnourished 
children. These three regimens have been chosen to reflect the spectrum of current 
opinion of the zinc requirement of the malnourished child.
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1.2 Linear Growth
1.2.1 Assessment
Linear growth is difficult to measure accurately and is assessed either as supine length 
or standing height. Supine length is best assessed in children less than two years using 
a baby board with supports for the head and feet. An assistant is required who holds 
the baby’s head in firm contact with the headboard so that line between the center of 
the auditory meatus and the lower border of the orbit (Frankfurt plane) is vertical. The 
measurer then straightens the child’s legs by gripping the ankles and takes the 
reading. The standing height of children over two years is measured using a 
stadiometer. The child should be in his/her bare feet with heels together, buttocks and 
shoulder blades against the stadiometer, looking straight ahead with a headboard 
resting at right angles against the highest point of the head. The measurer should 
ensure that the Frankfurt plane is horizontal and apply gentle pressure to the mastoid 
process to extend the head checking that the heels have not lifted off the baseboard 
(Cox 1992). Assessing height accurately in the two to three year age group is difficult 
and to obtain accurate measurements it is safest to measure supine length even in 
children up to five years old. Length or height should be reported to the nearest 0.1 
cm but it should be remembered that the measurement error is nearly 0.5 cm. The rate 
of change of height (velocity) has been promoted as a better expression of linear 
growth than height alone (Brook 1986), but inherent lack of precision in estimating 
velocity may limit its reliability in assessing growth in short children (Voss 1991).
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1.2.2. Indices & reference populations
Growth is measured using weight, height, mid upper arm circumference (MUAC) etc 
and sex and age. Single anthropometric measurements however are uninterpretable, 
and indices e.g. weight-for-height, are combinations of measurements that allow 
growth data to be compared within and between groups, e.g. a single weight is 
meaningless unless related to a child’s height or age. In turn, growth indices must be 
related to a reference population for meaningful interpretation. The WHO has 
endorsed the use of that population defined by the US National Center for Health 
Statistics (NCHS) as a reference (World Health Organisation 1995). However the use 
of references based on a population of infants and children from one country to assess 
the growth of children in another e.g. developing country, has proved controversial. 
Differences in the genetic potential for growth are often quoted as a rationale for 
having country or region specific growth references. However whilst genetic 
differences do exist, it is environmental factors that have the larger effect on the 
potential for growth. Martorell, who looked at the heights of school age children from 
different socio-economic groups in different countries, demonstrated that variation 
between height of the least socio-economically deprived groups in both developing 
and developed countries was less than the variation within countries between socio­
economic groups (Martorell 1985).
The WHO has acknowledged that reference data will be used as standards and 
recommends that care be taken to choose references that resemble standards (World 
Health Organisation 1986). It further acknowledges that since the mean heights of 
young children of many affluent populations differs little between ethnic groups it 
should be possible to construct a standard that reflects the growth potential of all
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children throughout the world. The WHO chose the NCHS reference because the 
population on which it was based lived in a healthy environment, was well nourished 
and had probably met its full growth potential. As a standard, its limitations must be 
recognized. The growth curves were originally constructed in 1975 from four sources. 
The 0 -23 month data of recumbent lengths came from the Fels Research Institute 
Longitudinal Study of 1923 to 1975. The infants included in this data set were 
predominately formula-fed and were from a relatively restricted genetic, socio­
economic and geographic background. The 2 -  18 y old data of standing heights came 
from three U.S. surveys from 1960 to 1975. Across most populations there is little 
difference in mean growth in height or in the distribution around the mean but the 
inclusion of both healthy and sick, breast as well as formula-fed infants in this 
reference should be remembered, particularly when comparing individuals or 
particular groups against the reference e.g. breast-fed infants (see below). With these 
limitations in mind, NCHS data should perhaps be used as a tool to identify children 
at risk of malnutrition rather than as a standard to be attained or as a means to label 
children as malnourished. An expert committee of the WHO has recently 
recommended the development of a new reference for infants and children, which will 
be a complex and costly undertaking (De Onis 1996).
Growth, however, is expressed as rate of change in weight, height etc (velocity), and 
can only be assessed by comparing indices over time against the reference population. 
In assessing individual children it must be emphasized that plotting a child’s weight 
and height over time allows assessment of the child’s own growth curve in relation to 
a reference population. Stunting is a deficit in height-for-age and signifies slowing of 
skeletal growth. In general, it reflects a chronic process. The prevalence of nutritional
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deficits varies with age and low weight-for-height often peaks in the second year of 
life, whilst low height-for-age starts earlier and decreases by three years.
Interpretation of these indices must take into account age. Thus a low height-for-age 
among one year olds reflects current health and nutrition, while among six year olds it 
suggests a past problem, but may also indicate concurrent stunting in the same 
population among younger children.
1.2.3. Growth -  the Infancy, Childhood and Puberty (ICP) model
Linear growth is a complex process occurring in three distinct phases -  infancy, 
childhood and puberty (Karlberg 1989). The infancy phase is a continuation of the 
high fetal growth rate with a rapid decline to three years of age. The onset of the 
childhood phase is heralded by an abrupt increase in linear growth rate and thereafter 
continues with a lower, more slowly decelerating velocity. A third distinct phase 
occurs at puberty before linear growth ceases and adulthood is reached.
These three phases contribute differently to overall linear growth. Maximal rate of 
growth occurs during the infancy phase, but it is the slower but longer childhood 
phase that is responsible for two-thirds of postnatal linear growth. The pubertal phase 
is associated with a second increase in growth velocity but is relatively short-lived and 
contributes least to the overall sum of linear growth.
The control of the infancy phase is poorly understood but is primarily a function of 
the intrauterine environment and postnatal nutrition. The onset of the childhood phase, 
normally in the second half of the first postnatal year, is influenced by the action of 
growth hormone (GH), which regulates long bone growth in the legs. Delays in onset
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of the childhood phase have attracted particular interest with regards to populations of 
malnourished children in developing countries and are proposed as a determining 
factor in attainment of final height (see page 32). GH continues its influence 
throughout childhood and adolescence but sex steroid secretion during puberty 
superimposes a further spurt in linear growth on the decelerating childhood phase.
The etiology and reversibility of stunting is best considered with reference to the ICP 
model. Changes in onset and duration of these phases and the effect of nutritional 
insults and interventions during them can be best understood within this context. For 
the purposes of this thesis I shall describe in more detail the infancy and childhood 
phases.
1.2.4. Stunting -  epidemiology
Stunting results from growth failure in childhood, which is commonly nutritional in 
origin. UNICEF estimates that 40% of the world under five population (226 million) 
are moderately or severely stunted. As a marker of deprivation stunting also predicts 
other functional consequences of severe nutritional insults early in life. Cognitive 
deficits, decreased work ability, increased morbidity and increased obstetric risks 
have all been associated with stunting. Stunted rural Guatemalan children had lower 
literacy scores, had completed fewer years at school and scored less well in tests of 
intellectual function than their normally grown peers (Martorell 1992). Adult height 
predicted the work capacity of Colombian sugar cane cutters (Spurr 1977), whilst 
shorter women with smaller pelvic sizes are at a greater risk of obstetric complications 
(Bamhard 1997; Tsu 1992).
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Stunting is a chronic process and it may take many months of sub-optimal growth 
before it occurs. The degree of stunting is a product of the severity, timing and 
duration of the nutritional insult. If a normal 12-month-old child stops growing 
completely then he will take 6 months to fall below -2 Z score for height-for-age i.e. 
stunted, whereas a 36 month old child will take 13 months to do the same. Equally 
that same 12-month-old will take 42 months to become stunted if he reduces his 
growth rate to 70% of normal as opposed to stopping growing completely (Golden
1994). Stunting results from a chronic insult and equally catch-up growth will have to 
be prolonged to reverse it -  the older and the more stunted a child, then the longer that 
he will have to grow at an accelerated rate before full catch-up growth is achieved. In 
the environment in which the vast majority of stunted children reside this is usually 
impossible.
In a study from Pakistan between 75-83% of children were stunted by 24 months of 
age (Karlberg 1993). The stunting process (defined as height-for-age Z scores) started 
at 6 months of age and continued to 18 months of age, whereas weight-for-length Z 
scores increased from a baseline o f-1 to 0 at 24 months. Other studies have found 
that length attained at three years is highly related to adult height but is independent of 
subsequent linear growth, i.e. that early growth retardation is not reversed later 
(Martorell 1995).
The requirement for dietary energy is highest in the first year of life when growth 
velocities are high but stomach volumes are low. Yet commonly used weaning foods 
in many countries with a high prevalence of stunting are bulky with energy densities 
too low to support optimal growth. Infections, especially gastrointestinal, are common
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in areas of poverty and illiteracy and contribute to malnutrition that makes children 
more susceptible to further infections. This cycle of poor nutrition and infection in 
this critical phase of growth leads to stunting.
The relative contribution of diarrhoeal disease and inadequate diet to the commonly 
observed growth failure of children in developing countries remains uncertain (Briend 
1989). At an individual level (Hoare 1996) diarrhoeal episodes cause short term 
faltering in both ponderal and linear growth, yet whether these children then catch-up 
and whether their long term growth failure is due to inadequate food intake or 
recurrent diarrhea is controversial. Malnourished rural Bangladesh children (Briend 
1989) grew equally well in the three monthly intervals where a diarrhoeal episode of 
at least 10 days occurred at the beginning of the interval compared with an interval 
with no diarrhea. In contrast intervals with at least 10 days of diarrhea occurring in the 
last 45 days were associated with significantly lower weight gain than those with 
diarrhea free intervals. These children were free of diarrhea for over 90% of the time 
but only gained weight to 74% of the NCHS median during diarrhea free periods. The 
authors concluded that these children were malnourished due to poor food intake 
rather than diarrhea. A review focusing on evidence of causality concluded that 
malnutrition was likely to predispose to diarrhea but that there was no conclusive 
evidence to support the hypothesis that diarrhea is a major cause of permanent growth 
faltering in whole communities (Briend 1990).
The recognition that diarrhea can be associated with intestinal mucosal injury suggests 
a mechanism. Recent application of non-invasive tests of mucosal integrity e.g. dual 
sugar intestinal permeability test, has permitted the study of the relationship between
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growth and mucosal injury. 119 rural Gambian infants aged 2 - 1 5  months had their 
growth measured and had intestinal permeability assessed monthly until 15 months of 
age during which time diarrheal morbidity was also recorded (Lunn 1991). All were 
breast fed until 3-4 months of age during which time their growth approximated to the 
50th NCHS centile but by 14 months both height and weight had fallen to the 5th 
centile. Intestinal permeability was strongly related to mean monthly weight and 
length growth and predicted 39% and 43% of the observed faltering in weight and 
length. Growth depressing intestinal permeability values occurred for 76% of the time 
yet the infants had diarrhea for only 7.3% of time. The intestinal mucosa of these 
children was abnormal for most of the time and the authors concluded that this was 
more likely to be due to gastrointestinal infection than malnutrition. Poor intestinal 
repair after injury was also demonstrated in 20 Gambian infants with persistent 
diarrhea and malnutrition who had no significant improvement in intestinal 
permeability one month into rehabilitation (Sullivan 1992).
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1.2.5. Prenatal influences
Intrauterine growth has a significant influence on post-natal growth and must be 
considered in the assessment of growth during infancy. Birth size is a reflection of 
gestational age, with those bom premature, but with an appropriate weight for 
gestation, usually demonstrating normal postnatal growth. Babies with a low weight- 
for-gestational age are termed light-for-dates. The relative degree of retardation of 
linear and ponderal growth can suggest causation. Those infants with length affected 
less than weight usually have a good postnatal growth prognosis and reflect a short 
term insult to intrauterine growth in late pregnancy, e.g. placental insufficiency. The 
baby with length and weight equally affected, however, reflects a more chronic 
process and the prognosis for postnatal growth is much poorer. Chronic fetal 
undemutrition, chronic maternal illness or malnutrition, toxin ingestion e.g. alcohol, 
tobacco, or genetic abnormalities can lead to proportionally small babies.
Growth hormone (GH) secretion is high during fetal life but does not influence linear 
growth of the fetus. GH deficient children are only 1-2 cm shorter on average than 
normal infants at birth (Karlberg 1988). GH receptors are present in cartilage but may 
be immature and whether this small discrepancy in linear growth is a result of this 
immaturity or a secondary metabolic action of fetal GH remains to be established. 
Anencephalic and athyroid fetuses do not demonstrate growth retardation indicating 
that both pituitary GH and thyroid hormone are not vital determinants of intrauterine 
growth (Vorherr 1982). Placental factors e.g. lactogen and somatomedins, may well 
influence intrauterine growth and need further study. Placental size and function 
clearly influence birth weight.
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The incidence of low birth weight (<2500g) in 1995 was 15.3% or 21.3 million 
newborns worldwide of which 20.4 million were bom in developing countries (De 
Onis 1998). IUGR (defined on the basis of birth weight below the 10th percentile of 
the birth weight for gestational age reference curve - De Onis 1996) in developing 
countries alone represents 30 million newborn infants per year or 23.8% of births. It is 
associated with increased mortality, and the strength of the association is greatest in 
the neonatal period but also extends post-neonatally. Infants weighing 2000-2499g 
were approximately four and ten times more likely to die in the neonatal period and 
two and four times more likely to die in the post-neonatal period than those bom 
weighing 2500-2999g and 3000-3499g respectively (Ashworth 1998)._Light for dates 
babies can demonstrate catch-up growth post-natally. Data from developed countries 
indicates partial catch-up growth can occur by two years of age and thereafter 
maintain that achieved place in the growth distribution until adulthood. Achieved 
adult sizes are on average 5 cm shorter and 5 kg lighter than controls (Martorell 
1998). In developing countries where the postnatal environment might be less 
favorable the effect is similar in absolute terms. The influence of body mass index 
(BMI) at birth for growth retarded children on subsequent catch-up growth is unclear. 
However birth length and predicted target height (a function of mid-parental heights 
indicating genetic potential) influences catch-up growth and explained half of the 
variation in catch-up growth in one study (Luo 1998). The effect of birth length 
predominated up to two years of age and thereafter target height dominated up to 
eight years. Pubertal catch-up growth in these children was small and was not 
influenced by fetal experience. Overall the difference in final height of these children 
was primarily attributable to the difference in the magnitude of catch-up growth
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during the first six months of life, confirming that this is the critical period for catch­
up growth.
1.2.6. Infancy phase of the ICP model
Infant birth size is linked to that of mother rather than that of father whose influence 
on growth becomes more apparent with time. If there is a large disparity between the 
size of father and mother then the likelihood increases that the baby’s growth will 
cross growth reference centiles either up or down. By the age of two years growth 
‘converges to the mean’ and genetic potential predominates as its principal 
determinant, and the centile trajectory leading to mid-parental height is achieved.
The infancy phase of growth represents a continuation of the fetal phase with a rapid 
deceleration of growth until three years of age when the childhood phase of growth 
predominates. Growth during infancy may continue to be influenced by the same 
factors that determined growth in utero, with nutrition pre-eminent. Human milk has 
long been recognized as the optimal food for babies, and complementary feeding is 
generally recommended as starting at around six months (World Health Organisation
1995). Longitudinal studies of infant growth in developing countries indicate that 
stunting occurs between the ages of four months and two years (see below), 
coinciding with the transition from breast feeding to complementary foods. The 
energy density of weaning foods has therefore been proposed as a factor in the 
etiology of stunting.
The timing of this transition has recently been questioned (World Health Organisation 
1998) and is of considerable importance, particularly in developing countries. The
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increased risk of disease associated with the introduction of microbial contaminated 
solid foods must be balanced against the risk of malnutrition from prolonged 
exclusive breast-feeding -  ‘the weanling’s dilemma’ (Rowland 1978). For a sound 
recommendation as to the optimal timing of complementary feeding an understanding 
of the growth of breast-fed babies is required.
The common observation of apparent growth faltering of breast-fed babies beginning 
at three to four months is based on the use of reference growth curves that were 
constructed from data from predominately formula-fed infants. Breast-fed babies have 
a different shaped growth curve, and gain less weight in the first year of life than 
formula-fed babies. Gaining less weight however does not necessarily imply that 
breast fed infants are not meeting their energy or nutrient requirements. Studies 
confirm that breast-fed infants have significantly lower energy intakes than formula- 
fed (Butte 1984) but this is not due to inadequate maternal milk production. Breast­
fed babies regulate their own milk intake (Dewey 1986) and may not consume all the 
milk in the breast during a feed. Despite lower energy intakes and weight gain babies 
exclusively breast-fed to four to six months of age have similar motor development 
and lower rates of infection than those formula-fed (Dewey 1991). Thus NCHS 
growth curves may reflect the ‘overfeeding’ of formula-fed babies rather than the 
‘underfeeding’ of breast-fed, and the growth of breast-fed babies in developing 
countries may be more appropriately compared with that of breast-fed babies of 
affluent populations.
Weight gain of breast-fed babies in developing countries is similar to that of breast­
fed babies from more affluent populations (Hijazi 1989) to six months of age although
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attained weight differs due to differences in birth weights. Ponderal growth faltering 
thereafter occurs at six months in those predominantly but not exclusively breast-fed 
and at nine months in those exclusively breast-fed to six months (World Health 
Organisation 1994). Linear growth however is poorer and breast fed babies from 
developing countries are generally shorter than those from developed countries. Infant 
linear growth is not exclusively a function of nutrition and when maternal height was 
controlled for the difference in length between Honduran and U.S. breast-fed babies 
disappeared (Cohen 1995).
It seems therefore that the growth rate of breast-fed infants in developing countries is 
similar to that of breast-fed infants of more affluent populations. Even if growth 
faltering occurs complementary feeding may not improve growth. The introduction of 
hygienic pre-cooked complementary food at four months of age did not improve 
growth before six months of age in a study of breast fed babies of low-income 
primiparous mothers in Honduras (Cohen 1994).
The timing of the introduction of complementary feeds however cannot be made on 
consideration of dietary intakes and growth alone. Infant morbidity, mortality and 
development as well as maternal considerations must all be included. It may well be 
that the optimal age of transition varies between populations. In affluent populations 
the benefit: risk ratio for complementary feeding at a particular age will differ from 
that of a population in a developed country, owing to the lower risk of contaminated 
complementary feeds.
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Being bom short or becoming short in the first two years of life is similar in terms of 
increased risk of adult shortness and thus it is not necessary to know whether a child 
was bom short or not in order to predict adult height. (Luo 1998)
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1.2.7. Childhood phase
The childhood phase describes the slowly declining growth rate throughout childhood 
into adolescence. Its onset is usually between six and twelve months of age, it is 
abrupt and probably represents the beginning of the influence of GH on linear growth. 
In children with isolated GH deficiency, this abrupt onset is lost (Karlberg 1988). 
Long bone growth is particularly dependant on GH and makes up the majority of 
growth in the childhood phase compared to the infancy phase when truncal growth 
accounts for the majority of linear growth (Karlberg 1990).
The trigger for the onset of the childhood phase is not understood but it is influenced 
by growth rate immediately prior to onset (Karlberg 1987). If a normal child has a 
small infancy component then onset is early compensating for poor gain. The age of 
onset will influence attained height subsequently -  growth attained between six 
months and three years of age is negatively related to the age of onset (Karlberg 
1990).
Late onset of the childhood phase is common in populations of children with 
disturbed growth patterns e.g. malnourished children from developing countries or 
children with a chronic disease such as coeliac disease (Karlberg 1988). This delay 
causes growth faltering and has been proposed as a determining factor in attainment 
of final height, particularly in developing countries (Karlberg 1994). The reasons 
behind this delay in onset remain to be identified but as the incidence of faltering 
clearly reflects socio-economic conditions it seems that environmental factors are 
more important than genetic. This view is supported by the observation that the 
growth rates of well-off members of society in these same developing countries do not
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falter or show delayed onset of the childhood phase. This phase and especially the 
first 6 months is the critical phase for catch-up growth (Luo 1998).
In the second year of life growth reflects the influence of both the infancy and 
childhood components. Seasonality, for the first time, affects linear growth, which 
fluctuates more in those populations with a delayed onset of the childhood component 
(Karlberg 1987). As the effect of the infancy phase disappears in the third year growth 
trajectory becomes more stable.
1.2.8. Reversibility of Wasting and Stunting
Ponderal catch-up growth is relatively easy to achieve in malnourished children 
through appropriate dietary rehabilitation and can be spectacular. Rates of 10-20 
g/kg/day can be generated -  up to 10 times the normal rate of gain in the under two- 
year old age group (Hoare 1996). The optimal macro and micronutrient content of 
rehabilitation diets has long been debated. Not only must pre-existing deficiencies be 
corrected but energy, protein and micronutrient content must match the potential for 
rapid growth -  if any one constituent is limiting growth may falter. Recent WHO 
recommendations summarize the requirements for energy, protein, potassium, 
sodium, zinc, copper as well as other minerals and water and fat soluble vitamins 
(World Health Organisation 1999). The exact requirements of severely malnourished 
children for many of the micronutrients in particular and when to administer them 
remains to be clarified.
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Linear catch-up growth is much more difficult to achieve. It can occur but its potential 
is limited, in particular, by the severity and length of the nutritional insult, the age at 
which it occurs and the age at which the potential for catch-up growth occurs.
In general babies are bom with the same mean length between and within populations 
of diverse socio-economic backgrounds. The process of stunting seems to occur 
between the ages of 6 and 18-24  months and is associated with a delay in the onset 
of the childhood phase of growth.
If a child in a developing country survives the critical growth period up to two years 
of age, then locally available foods with adequate energy density, and the 
development of the child’s immunity to local pathogens should allow the child to 
continue to grow at a normal velocity thereafter. The child will often remain at that 
baseline level of stunting, however, and demonstrate only marginal catch-up growth. 
The ability to catch-up linear growth has been demonstrated in studies of children 
adopted into better socio-economic conditions (Proos 1993). Even this catch-up 
growth in later childhood however is incomplete, and the effect on pubertal timing 
and final adult stature is not clear. The vast majority of children in developing 
countries stunted at two years of age will be left with a degree of stunting until 
adulthood (Golden 1994).
Nutritional interventions in the critical period (Schroeder 1995) of the first two years 
of life however can generate catch-up growth and reverse stunting. In Guatemala a 
study of food supplementation demonstrated a differential effect at different ages with 
only those under three years of age demonstrating catch-up growth and the linear
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growth of those three -  seven years not affected. The effect of nutritional 
interventions on stunted adolescents, their age and duration of menarche, and their 
final attained height is not known. However isolated reports point to the potential for 
catch-up growth even at this stage. Historical data on black American slaves of the 
19th century demonstrate marked stunting until these slaves reached working age i.e. 
15 -17  years old. Thereafter they were given a food supplement to facilitate work and 
demonstrated marked catch-up growth (Steckel 1987) with the females attaining final 
adult heights around the 35th NCHS centile at 25 years of age.
The potential for catch-up growth will depend both upon the environment; e.g. dietary 
macro and micro nutrient supply, patterns of morbidity and the predetermined height 
potential for that individual child. Height potential is genetically predetermined and 
normally reflects the parental heights in well-nourished populations. Comparing 
height potential for individual populations across the world it is clear that differences 
are primarily due to environmental factors rather than genetic. However parental 
height is not a reflection of genetic potential if children are bom to stunted parents. 
Animal experiments demonstrate that the progeny of rats that have been nutritionally 
restricted are small and even when their offspring have been adequately nourished it 
will take three generations or more for them to attain their true height potential 
(Stewart 1980). Thus it will probably take several generations of an optimal 
nutritional environment for the offspring of stunted parents to attain full genetic 
height potential. This process of environmental regulation of genetic potential is not 
clearly understood.
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In conclusion, the critical period for linear growth is under two years of age and 
significant nutritional insults before this age are likely to have profound and long term 
effects on growth. Ponderal growth is relatively easy to achieve but nutritional 
interventions designed to promote linear growth must be initiated early and be 
sustained. An understanding of the ICP model of linear growth and the relative 
contributions of each phase of growth underlies this. Stunting is not a benign 
adaptation to chronic nutritional insufficiency but has serious consequences in terms 
of general and reproductive health, school performance and intelligence and adult 
work capacity.
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1.3. Zinc
Zinc is essential for all forms of life. Its single oxidation state enables it to hydrolyse 
bonds such as those involving amino and carboxyl groups and enables it to form 
stable complexes with sulphur and nitrogen atoms. This allows for both the 
stabilisation of proteins and the facilitation of interactions both between proteins and 
with steroids or nucleic acids. It has structural and regulatory roles in many enzymes, 
signal transduction pathways and in gene transcription and is thus essential for 
metabolism, growth and reproduction. It plays a central role in protein, energy, 
carbohydrate and lipid metabolism, nucleic acid and haemoglobin synthesis, 
connective tissue turnover, tissue synthesis and gene transcription.
Up to 2 gm of zinc is present in an adult man but most (95%) is locked away in pools 
from which it cannot rejoin the circulation and influence plasma levels eg muscle and 
bone. Small plasma and liver pools are accessible and labile and act as the only 
reserve available in dietary deficiency. Zinc homeostasis is thus dependent on dietary 
intake and the average man has an intake of lOmg per day. It is absorbed throughout 
the small intestine involving specific and non-specific carrier mediated processes. 
Distal intestinal reabsorption of zinc is very important as there is a large entero- 
pancreatic circulation and the intestinal secretion of zinc can be at least twice the 
amount consumed daily. During episodes of deprivation zinc homeostasis depends on 
the liver and intestine with an increase in intestinal absorption and a decrease 
pancreatico-biliary secretion. Regulation of intestinal uptake is unclear but a defect at 
mucosal level is believed to underlie the inherited zinc deficiency disease 
acrodermatitis enteropathica. Meat is a good dietary source of zinc with plants also 
potentially good sources. However the presence of phytates in plants in practice often
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limits the availability of zinc from vegetable sources. Zinc is absorbed efficiently 
from breast milk but content (pmol/1) falls with time. Colostrum had a mean content 
of 71.9 to 176 pmol/1 at 7 days, 44.3pmol/l at 1 month, and 7.6pmol/l at 7 months 
(Casey 1989).
Zinc deficiency is often difficult to recognise as there are no characteristic clinical 
symptoms or signs associated with it. The classic features of isolated zinc deficiency 
were first recognised in Acrodermatitis enteropathica - a rare autosomal recessive 
syndrome of zinc deficiency that usually presents in the neonatal period with growth 
failure, diarrhoea and a circumorificial, retroauricular rash with acrodermatitis.
Zinc deficiency most commonly results from inadequate dietary intakes of 
bioavailable zinc. Zinc deficient populations were first described in Egypt and Iran 
(Prasad 1991). Subsequently deficiency has been reported from numerous developing 
countries particularly in S.Asia and S.America as well as from certain deprived socio­
economic groups in more developed countries such as Canada (Gibson 1989) and the 
U.S. (Walravens 1989). Populations with high levels of existing malnutrition, 
prolonged breast feeding and high phytate containing diets should be viewed as at risk 
of zinc deficiency. Simmer et al (Simmer 1990) measured the daily intake of zinc in 
breast fed Bangladeshi infants aged 1,2, 6, 9, and 12 months and found them to be 
between 10 to 30% of the National Academy of Sciences recommended dietary 
allowances. Important dietary sources of zinc include red meat, sea food and 
unprocessed cereals and nuts, but Brown et al (Brown 1982) demonstrated that 50% 
of Bangladeshi children had never received meat, fish or eggs by 30 months age.
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Zinc deficiency is an important public health problem. A meta-analysis of 25 
supplementation studies in Latin America & the Caribbean (n=8), N.America & 
Europe (n=8), Africa(n=3) and Asia (n=5) has shown a highly significant effect of 
zinc supplementation on both ponderal and linear growth in children less than 13 y 
old. Linear growth was only improved in children stunted initially and the magnitude 
of the effect on ponderal growth was inversely related to the plasma zinc 
concentration at entry. The authors concluded that in those settings with high rates of 
stunting and/or low plasma zinc concentrations, programs to enhance zinc status 
should be considered to improve children’s growth (Brown 1998).
Zinc deficiency rarely occurs alone and as its clinical features are not pathognomonic 
it is often not recognised other than as part of a global macro/micronutrient 
deficiency. However zinc can be a limiting factor particularly in anabolic states. 
Rehabilitation from severe malnutrition can be associated with spectacular ponderal 
growth rarely seen in any other physiological situation but linear catch-up growth has 
been more difficult to demonstrate and a permanent height deficit (stunting) often 
remains (Khanum 1998). Severity, duration and timing of the nutritional insult 
determine whether stunting ensues with those insults under 2 years of age causing 
maximal impairment of height velocity (Costello 1989). The promotion of linear 
catch-up growth in the stunted malnourished child is poorly understood but requires a 
prolonged period of ponderal catch-up often not achievable in the environment in 
which the child is recovering.
The control of linear growth and its relationship to ponderal growth is also not well 
understood. Walker and Golden (Walker 1988) examined catch-up growth in the early
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phase of rehabilitation from severe malnutrition retrospectively in a group of 369 
malnourished, hospitalised children to assess influences on linear growth. The 
subjects of their study did not demonstrate linear catch-up, but a subgroup, who were 
more stunted initially, did. Two-thirds of the group grew linearly only when they had 
attained 85% weight-for-length and they speculated that the diets were limiting in one 
or more nutrients essential for linear growth, such as zinc. They subsequently 
demonstrated that zinc promotes deposition of lean tissue in this period, which may 
influence linear growth potential (Golden 1992). Lean tissue synthesis increases when 
zinc is supplemented to severely malnourished children in addition to their 
rehabilitation diets. In Jamaica this same group showed that zinc supplementation 
reduced the energy cost of growth of severely malnourished infants on a soya-based 
high energy feed by favouring lean tissue deposition (Golden 1981).
The recommended dietary allowance of zinc for a one year old is 5mg/day (National 
Academy of Sciences 1989). A child recovering from severe malnutrition however is 
already deficient and in need of a higher dietary intake during the recovery process 
due to often spectacular rates of weight gain. Both the bioavailability of dietary zinc 
and the continuing losses in these children (due to the high prevalence of diarrhoea) 
also contribute to difficulty in estimating requirements in this group.
Supplementation trials carried out on malnourished children under three years have 
employed a diversity of regimens, and led to a variety of outcomes (table 1). 
Sempertegui (Sempertegui 1996) et al used 10 mg/d for 60 days and did not report 
any significant ponderal or linear growth effects. Schlesinger et al (Schlesinger 1992) 
used 2 mg/kg/day for 105 days and reported significant effects on linear growth only.
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Behrens at al (Behrens 1990) used 3- 4 mg/kg /d for 14 days in children recovering 
from diarrhoea and again reported significant effects on linear growth only. Khanum 
at al (Khanum 1988) used lOmg/kg/d for 21 days and reported significant effects on 
ponderal growth and did not report on linear growth.
Zinc deficiency is associated with poor immune function - particularly cellular 
immunity (Beisel 1982; Chandra 1984; Chandra 1991; Fraker 1982; Pekarek 1979) 
and zinc supplementation of malnourished children improves immune function 
(CastilloDuran 1987; Schlesinger 1992; Sempertegui 1996). Lymphoid atrophy, 
decreased delayed cutaneous hypersensitivity responses, reduction in numbers of T 
helper (TH) cells and deficient thymic hormone activity have been described in 
association with zinc deficiency. B cell dysfunction, and specifically impairment of 
phagocytosis, has also been described. This occurs through a down regulation of basic 
biological functions at cellular level including DNA synthesis, RNA transcription, cell 
division and activation. The secretion of cytokines is affected and free radical injury 
potentially increased as zinc also functions as an anti-oxidant and cell membrane 
stabiliser. Mild zinc deficiency was induced in a group of male volunteers and 
resulted in reduced serum thymulin activity and a reduction in the ratio of CD4/CD8
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Table 1: Zinc Studies -  dosage regimen and outcomes
Investigator Year Country Subjects Zinc regii
Bates CJ 1993 The Gambia RDBT 110 children between 0.57 and 2.3 
years
70mg twice we 
1.25 years
Behrens RH 1990 Bangladesh RDBT 64 malnourished children between 3 
and 24 months with acute diarrhoea
3-4mg/kg/d foi
Castillo-Duran C 1987 Chile RDBT of 32 marasmic infants 2mg/kg/d for 6
Gibson RS 1989 Canada DB pair matched study of 60 stunted boys 
aged 5-7y
lOmg/d
Golden MHN 1981 Jamaica 16 malnourished children 6-16 months 69 micomoles i 
per litre of feec
Halstead JA 1972 Iran 17 adults between 18 d 20 years with poor 
linear growth
27mg zinc dail;
Hambridge KM 1985 USA 107 children with poor linear growth 
between 2 and 6 years of age
0.2-0.3 mg/kg/i
Hemalatha P 1992 India RDBT of 33 malnourished children aged 1- 
5y
6mg/kg/d
Ronaghy HA 1974 Iran 49 boys prepubertal received 40 mg zinc 
day and control groups
40mg/d for 18
Simmer K 1988 Bangladesh 25 children with PEM 1-7 y 50mg/d for 2 w
Walravens PA 1989 USA 50 infants RDB pair matched 8-27mths of 
age with poor linear growth
6mg /d for 6 m
Walravens PA 1983 USA DB, pair matched study of 40 children 
between 2 and 6 years
5 mg/d for 1 ye
Cavan KR 1993 Guatemala DB study of 162 school children mean age 
81 months
lOmg/d for 25
Nakamura T 1993 Japan 21 prepubertal children with poor linear 
growth
5mg/d for 6 me
Shrivastava SP 1993 India Pair matched controlled study of 30 children 
with mild PEM aged 8-24 mths
5.6mg/d for 3 r
Schlesinger L 1992 Chile DBCT of 39 marasmic children mean age 7 
mths
2mg/kg/d for 1
Walravens PA 1976 USA DBCT of 68 full term normal infants 4mg/l of infant
Khanum 1988 Bangladesh 60 children with PEM between 5 and 60 
months
lOmg/kg/d for
Sempertegui 1996 Ecuador RCDBT of 50 children with PEM aged l-6y lOmg/dfor 60
RDBT- randomised double jlind trial
RCDBT -  randomised, controlled double blind trial
DBCT -  double blind controlled trial
DB -  double blind
NSD -  no significant difference
SD -  significant difference
lymphocyte ratio (Prasad 1998). IL(interleukin)-2 production was also reduced in the 
T-helper cells of the zinc deficient volunteers but production of IL-4,5,6,and 10 was 
unaffected implying an imbalance between TH 1 & 2 functions -  this is a potentially 
important pathway by which zinc deficiency affects cell-mediated immunity. The 
percentage of children under 3 yrs in India who remain anergic/hypergic to a battery 
of skin tests after 120 days of zinc supplements decreased from 67 to 47% and was 
associated with a significant rise in CD3, CD4 and the CD4/CD8 ratio (Sazawal 
1997).
Diarrhoea frequently accompanies malnutrition whether as an important cause or 
result of. Diarrhoea usually persists longer in malnourished children due to associated 
gut mucosal damage and cell-mediated immune malfunction. Zinc supplementation of 
937 children with acute diarrhoea in New Delhi resulted in clinically important 
reductions in the duration and severity in infants and young children (Sazawal 1995). 
Supplementation of children in India resulted in a significant reduction in the 
incidence of persistent diarrhoea in children >1 y old, and those with a low plasma 
zinc as well as on dysentery in boys (Sazawal 1996).
Zinc has also been recently noted to improve cognitive function in Chinese school 
children. 720 children aged 6-9 y old were given 20mg zinc supplements daily in a 10 
week double blind controlled trial with improvement in cognitive and 
neuropsychologic testing as well as growth (Sandstead 1998).
The available evidence points to zinc deficiency as an important public health 
problem in both developing and developed countries (Sandstead 1995).
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1.4. Collagen formation, degradation and osteoblastic activity
Bone is an active tissue undergoing continuous remodelling such that 10% of the adult 
skeleton is replaced each year. Linear growth is dependent on skeletal growth, which 
occurs when osteoblastic bone formation predominates over osteoclastic bone 
resorption. Bone is continually remodelled and longitudinal bone growth during 
childhood is dependent on GH (Nilsson 1994). The study of the biochemical markers 
of bone and collagen turnover allows for a better understanding of the physiology of 
growth as well providing a mechanism to describe both the pathological processes 
which disrupt and therapeutic interventions designed to promote growth.
Collagen comprises 90% of the organic matrix of bone and is produced by 
mesenchymal-derived osteoblasts. It is unique among proteins in the number of post 
translational modifications it undergoes. This includes among many others the 
hydroxylation of proline and lysine residues in the rough endoplasmic reticulum to 
form hydroxyproline and hydroxylysine. Certain hydroxylysine residues are then 
glycosylated to form O-linked glycosides. Collagen is synthesised as procollagen 
which is about 50% larger than the final or fibrillar collagen due to extension 
polypeptides at each end of the molecule. Association of the three procollagen chains 
and winding up of the helix is driven by the formation of disulphide bonds within the 
C terminal propeptide. The helical molecule is then transported to the Golgi 
apparatus where carbohydrate additions are made to the non-helical sections. The 
molecule is then secreted actively and the N and C terminal propeptides are removed 
by specific proteases. The helical molecules then spontaneously associate into fibrils 
in a quarter staggered array. The final extracellular modification is the oxidative
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deamination of specific lysine or hydroxylysine residues which determines the tissue 
specificity of the resultant collagen molecule -  lysine oxidation in skin leads to the 
formation of histidine based cross-links and hydroxylysine oxidation in cartilage and 
bone leads to the formation of pyridinium based crosslinks
There are currently about 15 types of collagen described. Collagen type 1 is the main 
constituent of bone and skin and collagen type 3 is essentially absent from bone but is 
widely distributed in most soft tissues. The principal product of the mature osteoblast 
is type 1 collagen that makes up 90% of protein in bone.
The pyridinium crosslinks formed in the final stages of type 1 collagen maturation are 
good candidates as markers of insoluble collagen degradation as they are 
quantitatively excreted in urine either free or peptide bound. Pyridinoline (PYD) has a 
wide distribution other than just in bone e.g. cartilage, ligaments and tendons but 
since these other pool sizes are relatively small they contribute little to urinary output. 
Its analogue deoxypyridinoline (DPD) is more specific to bone and shows less 
variance than PYD in urine. It has been found in other tissues but since their turnover 
is so slow then the presence of DPD in urine can be regarded as specific for bone 
(Robins 1994).
Collagen type 1 cross linked C telopeptide (1CTP) is a PYD and DPD containing 
peptide located at the C-intermolecular site of the collagen fibril. Serum levels 
correlate with bone resorption (Calvo 1996). Urinary DPD is currently regarded as the 
best overall test of bone collagen breakdown but as it is difficult to collect timed urine 
samples from children random urines are often used and excretion of markers is
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expressed in relation to creatinine. As this reflects muscle mass a further element of 
variability is introduced (Robins 1994) and plasma or serum levels of 1CTP are used 
in an attempt to overcome this.
The carboxy-terminal propeptide of type 1 collagen (PI CP) is one of the propeptides 
cleaved extracellularly during formation of fibrillar collagen and serum level reflects 
type 1 collagen synthesis. PI CP is not metabolised but rapidly cleared intact by the 
liver. Although present in skin the mass and turnover of bone is such that most serum 
PI CP should come from bone and levels are closely related to histomorphometrically 
assessed bone matrix formation (Eriksen 1993). Indeed serum PI CP predicted 
response in prepubertal children treated with growth hormone -  the percent increase 
in PI CP after 3 months was correlated to the increase in height velocity at 12 months 
(Trivedi 1991). Type 3 collagen is more widely distributed and is not present in bone. 
The N terminal propeptide of type 3 collagen (P3NP) reflects soft tissue formation 
and has been used also as a growth marker. P3NP response after 5 weeks predicted 6 
month growth response to growth hormone therapy (Tapanainen 1988).
Bone specific alkaline phosphatase (BAP) is a zinc containing enzyme associated with 
the plasma membrane of the osteoblast. It is needed to hydrolyse pyrophosphate, a 
potent inhibitor of calcium phosphate deposition. It has been found to correlate with 6 
month height velocity in short normal children treated with growth hormone (Crofton 
1995). Its response to new bone formation is more specific than PI CP but slower as 
production of PI CP is an early event taking place during proliferation of osteoblast 
precursor cells and expression of BAP starts after cessation of cell proliferation 
(Schonau 1997).
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1.5. Insulin like growth factor and binding proteins
Linear growth is dependent on skeletal growth, which is the result of chrondocyte 
proliferation and subsequent endochrondral ossification in the epiphyseal growth 
plates of long bones. Growth occurs when osteoblastic bone formation predominates 
over osteoclastic bone resorption. Bone is continually remodelled and longitudinal 
bone growth during childhood is dependent on growth hormone (GH) (Nilsson 1994). 
Control of resorption and formation is complex with evidence pointing to the 
components of the GH/IGF (insulin like growth factor) axis as providing the 
complexity required to selectively regulate complementary processes to suit demands. 
GH and insulin like growth factor 1 (IGF1) have different target cells in the 
epiphyseal growth-plate. GH stimulates slowly dividing prechrondrocytes in the 
germinative cell layer while IGF1 promotes the clonal expansion in the proliferative 
layer of the GH primed cell (Nilsson 1994).
IGF’s regulated osteoblast and osteoclast proliferation and collagen synthesis in vitro 
(Rosen 1994) and recombinant IGF1 stimulated bone formation in women (Johansson 
1992). Locally produced IGF’s acting as autocrine or paracrine agents have been 
postulated as mediating in the coupling of bone formation to resorption (Hayden 
1995; Chihara 1997).
IGF1 is a 7.6kD polypeptide produced both in the liver and locally in multiple cell 
types in response to a combination of autocrine, endocrine and paracrine factors to 
promote cell growth. The major regulator of circulating IGF1 is GH (Hynes 1987). 
Liver produced IGF1 determines circulating levels but skeletally produced IGF1 also 
contributes. Whether plasma IGF1 reflects local tissue levels is not clear. IGF1 has
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short term metabolic actions similar to insulin and longer term mitogenic actions in 
the epiphyseal growth plate. IGF1 also promotes type 1 collagen synthesis, increases 
proteoglycan synthesis in chrondrocytes, and inhibits skeletal specific collagenases 
(Rosen 1994). Plasma levels of IGF 1 have been used primarily for evaluation of GH- 
secretion but do show some circadian rhythm.
Insulin like growth factor binding proteins (IGFBP’s) transport IGF’s, control tissue 
specific availability, regulate clearance, modulate receptor interaction with the IGF’s 
and have a direct effect on cells (Clemmons 1998). There are 6 IGFBP’s described 
currently and they are found in all physiologic fluids. Their affinity to IGF1 is greater 
than the IGF1 receptor and they thus act to partition the IGF’s among 3 sites -  
interstitial fluids, IGFBP’s bound to cell surfaces or extracellular matrix and type 1 
receptors. The relative affinity that the IGFBP’s have for IGF1 is regulated by 
whether the IGFBP is bound, and whether they undergo proteolysis or 
phosphorylation (Clemmons 1998). IGFBP3 is the principal IGF binding moiety and 
its concentration is regulated by GH. Among the IGFBP’s it circulates in the highest 
concentrations and it has the highest affinity for IGF1. IGFBP3 exists in the 
circulation as a 150kD complex with an acid labile 85kD glycoprotein. Release of 
IGF1 from this complex is thought to occur following a lowering of pH and is 
mediated by IGFBP proteases. As IGFBP3 levels modulate IGF1 availability they 
might reflect GH secretion better than IGF1 however both are currently used for such. 
IGFBP2 circulates in concentrations of approximately 1/10 of IGFBP3 and its 
concentration is inversely regulated by GH (Smith 1993) such that on administration 
of GH there is an increase in IGF1 and concomitant decrease in IGFBP2.
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Nutritional factors are important regulators of the GH-IGF1 axis and malnutrition 
leads to a state of GH resistance (high GH, low IGF 1 and high IGFBP2 levels) which 
may represent an adaptive mechanism to promote lipolysis and fatty acid oxidation 
whilst attenuating the anabolic actions of GH on protein synthesis (Soliman 1986). 
Animal studies demonstrate that nutrient availability regulates GH action at multiple 
levels with reduced GH binding capacity, post GH receptor defects, reduced IGF1 
gene transcription and translation demonstrated in fasted or protein restricted rats as 
well as increased IGF1 clearance (Thissen 1991; Thissen 1990; Maes 1988). IGF1 and 
IGFBP2 decrease rapidly in rats in response to nutritional insults whilst IGFBP3 
concentrations decline only in prolonged fasting or protein deficiency (Lewitt 1994; 
Maes 1983).
IGF1 levels in children declined in response to 6 days of protein or energy restriction 
with an associated increase in IGFBP2 in protein restriction only (Smith 1995). Levels 
of IGFBP3, the principal carrier of IGF 1, are more consistently reduced in humans by 
prolonged malnutrition along with IGF1 (Ketelslegers 1996). When malnourished 
Bangladeshi children recovering from Shigellosis were fed either a normal protein 
(6% of total dietary energy) or high protein diet (12%), better weight gain, higher 
IGF1 levels and a larger decrease in IGFBP2 levels were noted in the high protein 
group (Pucilowska 1993). IGFBP2 is highly dependant on dietary protein intake and 
may be useful in monitoring the response to refeeding in children who have been 
ingesting suboptimal amounts of protein (Smith 1995).
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1.6. Knemometry
Knemometry is the measurement of the distance between the knee and the heel and 
was first described by Valk in 1983 (Valk 1983). The technique has been proposed as 
the technique of choice for short term growth studies as it allows for accurate and 
repeatable measurements of lower leg length. It is a robust, sensitive and precise 
technique. The estimated technical error (mean coefficient of variation) for measuring 
standing height with a stadiometer has been assessed as 2.0-3.0mm (Voss 1991) 
whilst Valk described a technical error of 0.09-0.16mm with a fixed knemometer. 
Subsequent to this portable knemometers have been developed with technical errors 
of 0.27mm (Davies 1996). The lower leg however does not grow smoothly and 
variations in growth rate are seen in healthy children with a marked day-to-day 
variation of lower leg length that exceeds the error of the measurement itself 
(Hermanussen 1988). Lower leg growth is pulsatile and consists of sharp growth 
spurts alternating with periods of decreased growth velocity (Lampl 1992) 
(Hermanussen 1988). The sensitivity of this technique has also raised concerns that 
knemometry also detects changes in soft tissue. Daily fluctuations in weight were 
weakly associated to fluctuations in knemometric length in children over 2.4y 
(Hermanussen 1988). In infancy and early childhood however long bone growth is 
maximal with a height velocity of about 50cm/year in the first few months of life. The 
accuracy of this technique and this growth rate in infancy allow for accurate 
assessment of lower leg growth over days and weeks during this period.
Knemometric length does display a diurnal variation (Valk 1983) and physical 
activity prior to measurement does lead to a significant decrease in lower leg length 
(Hermanussen 1988). Knemometric growth can occur at a steady rate but also in
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spurts and shrinkage has been demonstrated which might be associated with catabolic 
stress (Wales 1987).
Lower leg growth is dependent on long bone growth and lower body segment growth 
makes up to 84% of total linear growth in the first few years of life (Karlberg 1990). 
However knemometers do not predict long-term total linear growth very well (Wales 
1987). The correlation coefficient between annual height velocity and a 1 month 
knemometric increment was 0.07, and with a 3 month increment was 0.437 and with a 
6 month increment was 0.73 (Dean 1990). In 12 girls with Turner’s syndrome treated 
with GH a 1 month increase in lower leg length had only a 50% positive predictive 
value in total linear growth (Wales 1989). Total linear growth is also dependant on the 
growth of short bones in the spine and different parts of the skeleton appear to grow at 
different rates and times (Roche 1974). Knemometry is also more technically difficult 
than height or length assessment.
Knemometry has found a niche in assessing short-term responses to therapeutic 
interventions. Asthmatic children aged 7-14 ys old given inhaled beclomethasone 
dipropionate had significant suppression of lower leg growth rate compared to 
children given inhaled fluticasone (Wolthers 1997). Growth hormone deficient 
children had significant increases in lower leg length 24hrs after a single dose of 
human growth hormone (Hermanussen 1985).
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Chapter 2: Methods
2.1. Location
The study was part of a collaborative effort between the Bangladesh Institute of Child 
Health and the University of Edinburgh, Scotland. It took place at the Nutritional 
Rehabilitation Unit (NRU) of the Dhaka Shishu Children’s Hospital in Dhaka, 
Bangladesh. Bangladesh has an estimated 120 million people, 17 million of whom are 
under 5 years old. 86% of the population live in absolute poverty i.e. that income level 
below which a minimum nutritionally adequate diet and essential non-food 
requirements are not affordable. Extreme and widespread poverty is manifest in the 
infant mortality rate and national nutrition indicators. 91 per 1000 children die in 
infancy and 67% of the under 5 population are moderately or severely underweight
i.e. (>2 standard deviations from median NCHS weight for age) (UNICEF 1996).
The hospital is the only paediatric hospital in Dhaka -  a city of 13 million, and the 
unit is the biggest of its kind in the city. The hospital is locally run and financed -  
40% of its beds are ‘pay’ beds generating the revenue required to finance the other 
60% ‘free’ beds. These beds are open to anyone who presents unwell to the hospital 
with only a minimal charge. Due to the overwhelming clinical need however the free 
beds run at 100% occupancy and financial resources are always stretched. Each unit 
within the hospital also had a degree of autonomy to raise money that it could spend 
on itself. As there were rarely any children of the ‘better-ofF social groups admitted 
to the Nutritional Rehabilitation Unit this resulted in the NRU having relatively fewer 
resources than the other hospital units.
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The NRU had 20 beds and was continually full. Severely malnourished children were 
admitted directly from the ‘out-patient’ department that effectively operated as an 
accident and emergency unit or from other hospital units. The unit was run by a senior 
dietician, with input from 3 hospital physicians and nursing support. The first 4 
months of the project involved the development and introduction of an agreed clinical 
protocol for the management of the severely malnourished child as detailed below to 
be used by all staff.
The average length of stay on the unit was 11 days and reflected the intense social 
pressure on the mothers not to remain in hospitals as many were working particularly 
in the garment industry. This had led to the use on this unit of ‘aggressive’ refeeding 
strategies using nasogastric (NG) tubes to increase energy intakes during the initial 
phase of anorexia associated with severe malnutrition and sepsis.
Defined discharge criteria were not developed nor was follow-up arranged or health 
education promoted. Under the agreed protocol daily health education discussion 
sessions were introduced, a follow-up clinic was established and discharge guidelines 
were promoted.
Nasogastic feeding of 
anorexic and often 
septic severely 
malnourished children
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Oxygen, broad-spectrum antibiotics and both oral rehydration and intravenous fluids 
(the use of which was discouraged) were available on the unit. Stool microscopy and 
culture, chest Xray, haemoglobin estimation, plasma sodium, potassium, protein and 
glucose estimation were all available on the unit between the hours of 0900-1200 
only.
Mothers were integral to the process 
of nutritional rehabilitation being 
responsible for basic care, feeding 
and stimulating the children as well 
as taking part in the health education 
sessions.
Mothers were resident with their children sleeping in the same bed as them and were 
integral to the philosophy of the unit being responsible for basic care and feeding and 
invited to a health education discussion everyday.
Health education 
discussion groups
The ethos of nutritional rehabilitation should involve a significant element of health 
education particularly where children are likely to be discharged quickly back into the 
same environment in which they became malnourished. This involved a 15-day 
rolling programme of 45 minute group discussion sessions led by a dietician on a
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variety of topics including breast feeding promotion, healthy weaning, cooking, food 
choices and availability, immunisations, diarrhoea management and the use of oral 
rehydration solution as well as family planning.
Breast-feeding was 
actively promoted as 
part of the health 
education discussions
Breast-feeding was actively promoted on the unit and health education aimed to 
encourage the effective nutritional use of local dietary resources available to feed 
children.
Discharge guidelines included a suggestive minimum of 15 days in hospital, the 
disappearance of oedema and anorexia, the establishment of catch-up growth without 
the use of an NG tube, and no evidence of sepsis. Close out-patient follow-up was 
arranged to ensure continued catch-up growth, to monitor morbidity, to re-enforce 
health education and ensure completion of the Bangladesh EPI (expanded programme 
of immunisation) schedule.
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2.2. Study children
141 children, who fulfilled the criteria below, were enrolled sequentially from those 
admitted to the unit over a 13 month period from November 1995 till November 
1996. All were aged between 6 and 36 months, with a weight-for-age less than 60% 
of the NCHS median for age and/or had nutritional oedema. They were clinically 
stabilised within a week after admission (i.e. acute complications of severe 
malnutrition being treated and able to commence and tolerate the oral nutritional 
rehabilitation regimens). Children in whom there was a strong suspicion of underlying 
tuberculosis (i.e. those children with a tuberculosis contact history and a history of 
prolonged temperature or cough) were not recruited. All children lived within two 
hours travelling distance of the hospital, and their carers agreed that their child would 
remain in hospital for a further 15 days and be followed up for total of 90 days.
Selection criteria
1. Aged 6 to 36 months
2. Weight for age < 60% of NCHS median and/or nutritional oedema
3. Within 1 week of admission to hospital
4. Able to tolerate enteral feeds
5. No clinical suspicion of tuberculosis
6. Live within 2 hrs of the hospital
7. Agreed to follow-up period.
8. Fully informed consent (see below)
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2.3. Clinical management protocol
Mortality rates among severely malnourished children vary between units with reports 
of up to 60% mortality among oedematous malnourished children. A recent review 
pointed to faulty case management with inappropriate diets high in protein, energy 
and sodium and low in micronutrients commonplace (Schofield 1996). The WHO has 
encouraged the use a clinical protocol based approach with the usage of standardised 
diets and antimicrobials encouraged and as recently produced such a suggested 
protocol (World Health Organisation 1999).
On recruitment all children were examined and investigated for infection as deemed 
clinically appropriate. All were treated with broad spectrum antibiotics (usually 
Ampicillin and Gentamicin) if not already receiving them. If there was a history of 
invasive diarrhoea either nalidixic acid or mecillinam were prescribed (reflecting the 
local sensitivity patterns of Shigella) and skin sepsis was treated with cloxacillin.
They then received liquid dietary regimens with gradually increasing energy densities 
and protein contents. The volume of feed offered on a particular day depended upon 
type of malnutrition, the presence of diarrhoea and number of days after recruitment.
The liquid diet used was dried skimmed milk-based (264 kJ, 2.2g protein and 0.3 mg 
zinc / 100ml) unless diarrhoea was present when a rice-based (259 kJ, l .lg  protein 
and 0.3mg Zinc / 100ml) was substituted (see appendix 1). These were delivered in 
two hourly feeds initially at 80 mls/kg/day in oedematous malnutrition or at 120 
ml/day in non-oedematous malnutrition with incremental steps of 15mls/kg/day up to 
200mls/kg/day over the course of their in-patient stay. These liquid diets were 
administered by gravity feed through a nasogastric tube initially until appetite
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improved enough for children to take the full volume offered by mouth. Breast­
feeding was encouraged and solid food was offered ad libitum. All subjects on 
admission were given vitamin A (retinyl palmitate - 200,000 i.u if over 1 year and 
100,000 iu if under) and on recruitment were given daily doses of a multivitamin 
supplement (3000 iu vit A, 30mg vit C, 600 iu vit D, 0.96 mg thiamine, 0.6mg 
riboflavin, 0.6 mg pyridoxine and 6mg of nicotinamide). Iron supplementation of 
acutely unwell severely malnourished children has previously be shown to be 
dangerous (Smith 1989) and was used only in response to an iron deficient blood film 
taken on day 30 of the trial.
Days 1-15 consisted of in-patient intensive nutritional rehabilitation and health 
education. The mothers were responsible for primary care of their children and slept 
with them at night. They collected and dispensed the liquid feed every 2 hours from 
the nursing staff as well as being responsible for the basic hygiene of the child. The 
nursing staff administered the ward, dispensed medication and diets and recorded 
clinical observations. The ward nutritionists were responsible for the feeds and 
recorded anthropometric and knemometric observations as well as compiling an 
individual data file on each patient. They also organised and ran a health education 
programme which consisted of nutritionist led discussion groups for 45 minutes each 
day on a rotating series of topics e.g. promotion of breast-feeding, healthy weaning, 
treatment of diarrhoea and use of oral rehydration solution, promotion of 
vaccinations, family planning and cooking.
Whilst every effort was made to standardise feeding regimens it was recognised that 
estimated energy intakes were inaccurate. As part of the health education component
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of rehabilitation encouraging the mums to use locally available food resources 
effectively was stressed. Solid foods offered to the children were chosen so that they 
could both be cooked and resourced locally by the mothers. As a result consistent 
energy and protein contents of the solid foods in particular were impossible to 
maintain.
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2.4. Randomisation and Zinc supplementation
Stratified randomisation into three zinc supplementation regimens was performed by 
an independent observer using variable length blocks within six strata generated by 
age (<13 months and 13-36 months) and type of malnutrition (marasmus, marasmic 
kwashiorkor and kwashiorkor as defined by the Wellcome classification).
The regimens were chosen to reflect the diversity of current opinion of the zinc 
requirement of the malnourished child (see introduction -  table 1) based on previously 
published trials
1. Regimen 1:1.5 mg/kg/day (mg of elemental zinc per kg body weight of zinc 
sulphate) for 15 days followed by placebo for 15 days,
2. Regimen 2: 6.0mg/kg/day for 15 days followed by placebo for 15 days
3. Regimen 3; 6.0mg/kg/day for 30 days.
A placebo group was not included after extensive consultation in Bangladesh. The 
majority of malnutrition rehabilitation units had very recently decided that the 
evidence for benefit was such that randomising malnourished children to placebo was 
unethical.
The zinc sulphate and placebo suspensions were indistinguishable and both were 
formulated and provided by Ciba-Geigy, Bangladesh (see appendix 2). All bottles 
were identical and labelled sequentially 1-300. On recruitment to the study 2 bottle 
numbers were provided by the independent observer and the corresponding bottles 
were then selected for that patient and labelled as either bottle A for days 1-15 (either 
1.5mg/kg or 6.0mg/kg) and bottle B for days 16-30 (either 6.0mg/kg or placebo). The
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mothers were instructed on how to administer the supplement using labelled syringes 
which they continued to use at home up to day 30.
2.5. Discharge and follow-up
There is tremendous pressure on mothers to take their children out of hospital as soon 
as possible in Dhaka for economic reasons. Also when the child’s acute infection is 
treated there is often poor recognition of malnutrition as a problem in a society where 
malnutrition is endemic. Prior to commencement of the study the median length of 
stay was 11 days. No outpatient follow-up was organised as attendance had been poor 
and the hospital authorities felt that scare resources could be better spent.
Our subjects were discharged on day 15 on agreed discharge guidelines. Specifically 
these stipulated that the child should remain an inpatient until at least day 15, the 
disappearance of oedema and anorexia, the establishment of catch-up growth without 
the use of an NG tube, and no evidence of sepsis.
A prospective study of 437 severely malnourished children followed up for 1 year in 
Dhaka demonstrated that morbidity was high, with a mean of seven episodes of 
diarrhoea during the year (Khanum 1998). Outpatient visits for diarrhoea occurred for 
67% of children, and 58% had pneumonia (10% had pneumonia three times). It was 
concluded that ‘the high prevalence of illness highlights the need for continued 
accessible health care and for interventions to reduce disease acquisition’.
We instigated a follow-up clinic after discharge. To encourage attendance a study 
nurse would visit homes of discharged children if they had missed an appointment.
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Cost of rickshaw journey was re-imbursed to families on attendance. We planned to 
follow-up all children on days 21, 30,45, 60, 75, and 90 when anthropometric and 
knemometric data were recorded and health education re-enforced. All children were 
examined, infections treated and completion of vaccination schedules promoted. The 
last blood and urine sample was collected on day 30.
2.6. Ethical approval and informed consent
The study was approved by the Paediatrics and Reproductive Medicine Research 
Ethics Sub-Committee of Lothian Health, Edinburgh, the Ethics Committee of the 
International Centre for Diarrheal Disease Research, Bangladesh and the Dhaka 
Shishu Children’s Hospital management committee.
Informed consent was obtained from the primary carer of each child. As most carers 
could not read a standard statement was read out to them in Bengali describing the 
nature, aims and methods of the study (see appendix 3). It was made clear to the 
carers that the care of their children would not be affected if they declined to take part 
in the study. If they agreed to take part then they signed/marked a consent form which 
was in Bengali and was read out to them. It was also made clear that they could 
withdraw from the study at any time and that the care of their child would not be 
affected. Strenuous efforts were made to ensure that the carer understood all of the 
above.
2.7. Anthropometry
During the in-patient phase body weight was recorded daily, knemometry on alternate 
days and all other anthropometric variables on days 1, 8, and 15. During follow-up all
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nutritional measurements were recorded together on the morning of follow-up.
Weight was recorded on an electronic scales (Seca model 835, Todd Scales Ltd, 
Newmarket, UK) with graduations to 20 grams, and all length measurements were 
performed supine on a Rollameter (Raven Equipment Ltd, Great Dunmow, Essex,
UK) with graduations to 1mm. Skinfold thicknesses were measured with calipers 
(Holtain Ltd, Crosswell, Dyfed, UK) graduated to 0.2mm and a standard non-stretch 
tape-measure was employed to measure mid upper arm circumferences with 
graduations to 1mm. Knemometry is the measurement of the distance between the 
child’s knee and heel measured here with the child sitting and the knee held in flexion 
of 90 degrees (photo 1). The knemometers were manufactured by the medical physics 
department of the Royal Infirmary Edinburgh and measured to 0.1mm. Two observers 
undertook all of the knemometry, skinfold and mid upper arm circumference 
measurement after an eight week training period. Five knemometric readings were 
taken at each assessment and the mean was accepted unless the standard deviation 
was greater than 1mm (chosen to represent a coefficient of variation of 1% of the 
average knee-heal length in this group). Weight and length were measured by a team 
of four nurses and four nutritionists who undertook an eight week training course 
before the study commenced. All staff involved in anthropometric data gathering were 
subject to regular, unscheduled, formal assessments of measurement technique.
Knemometry
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2.8. Biochemical assays
Samples were collected on recruitment, days 15 & 30 and every effort was made to 
co-ordinate with routine clinical investigations. All blood and urine samples were 
taken between 0900 and 1100 hours. Plasma (1ml) and serum (1ml) were separated 
off immediately and stored with urine (3mls) at -20°C. All assays were carried out 
either in the Department of Biochemistry of the Royal Hospital for Sick Children, 
Edinburgh or Department of Pathological Biochemistry, University of Glasgow.
CRP was measured by an in-house ELISA assay on Nunc Immuno 1 micrititre plates, 
using DAKO rabbit anti-human CRP antibodies and calibrated with DAKO Human 
CRP calibrator. The samples were incubated overnight in plates pre-coated with anti­
human CRP. After washing a sandwich was formed by adding anti-human CRP-HRP 
conjugate followed by a second wash and addition of a chromogenic substrate. After 
15 mins incubation the reaction was stopped and the colour read. The precision was 
6-8% at values of 0.2-9.9mg/l. Plasma Zn/Cu was determined by an in-house atomic 
emission method (inductively coupled plasma -  atomic emission spectroscopy). The 
precision ranged from 2-5% at concentration of 4-15 micromol/1.
IGF1 was measured in plasma using a specific RLA (Mediagnost, Tubingen, 
Germany). This assay employs an excess of IGF2 to eliminate interferences by 
IGFBPs (Blum 1994). The between-assay coefficient of variation was <9%. IGFBP3 
was measured in plasma using a specific RIA as described (Blum 1990). The 
between-assay coefficient of variation was <8%. IGFBP2 was measured in plasma 
using a specific RIA (Elmlinger 1996). Recombinant human IGFBP-2 (a gift from 
Sandoz, Basel, Switzerland) was used as standard and tracer. The between-assay
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coefficient of variation was <11%. PICP, ICTP and P3NP were measured in plasma 
by RIA (Orion Diagnostica, Espoo, Finland). Before analysis, samples were diluted 
appropriately in 154 mmol/L sodium chloride to achieve concentrations within the 
calibration curve; typical dilutions were 1:4 for PICP and 1:2 for ICTP and P3NP. All 
samples were analysed in duplicate. Samples from each patient were analysed in a 
single analytical run to minimise analytical variation. Within- and between-run 
coefficients of variation were <5% and <8% for PICP, <6% and <10% for ICTP, and 
<6% and <7% for P3NP. Bone ALP was measured in plasma by an enzyme-linked 
immunosorbent assay (Alkphase-B™; Metra Biosystems Europe, Oxford, UK). This 
assay utilises a monoclonal anti-B AP antibody coated on a microtitre plate to capture 
BAP in the samples. Cross-reaction with liver alkaline phosphatase is stated by the 
manufacturer to be 5%. All samples were analysed in duplicate. Within- and between- 
run coefficients of variation were <6% and <8% respectively. PYD and DPD were 
measured in urine by HPLC using a modification of the method of Pratt et aL, as 
described (Pratt 1992), (Crofton 1998). Pyridinium cross-links extracted from 
demineralised sheep bone (kindly donated by Dr Simon Robins, Rowett Research 
Institute, Aberdeen, UK) were used as external standards. Results were expressed in 
relation to creatinine measured on the same urine sample. All samples were analysed 
in duplicate. Between-run coefficients of variation were 6% for PYD and 9% for 
DPD.
2.9. Reference data
Reference ranges of normality were limited on many of the biochemical markers of 
collagen and bone turnover as they were relatively new assays. Reference values for 
all biochemical data were chosen from that published from well nourished European 
children of similar age. The 95% reference ranges (2.5-97.5 percentiles) and median 
for IGF1 and IGFBP3 were 17.6-195.9mcg/l and 57.9mcg/l and 967-3224mcg/l and
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1878mcg/l respectively. The 95% reference ranges (2.5-97.5 percentiles) and mean 
for IGFBP2 were 335-748mcg/l and 522 mcg/1 respectively (Blum 1996). The 
reference range and median for PICP, P3NP and ICTP were taken from data on 
Edinburgh children and were 290-1316 and 488 mcg/1, 5.1-22.3 and 11.6 mcg/1, and
6.9-27.7 and 14.5 mcg/1 respectively (Crofton 1997). The reference range and median 
for BAP were 36-100 and 61 units/1 respectively (Crofton 1995). The reference range 
for PYD and DPD were 200-700 and 30-120 nmol/nmol creatinine respectively 
(Zanze 1997). The inherent problems in comparing biochemical assays of bone and 
collagen turnover between malnourished Bangladeshi children and well nourished 
European children of similar age must be appreciated and these reference data are 
thus only mentioned in the text of the results for comparison.
2.10. Statistics
Sample sizes were calculated with a requirement for 90% power at the 5% level to 
show a difference between groups for 11 anthropometric and biochemical outcome 
variables, and a sample size of 60 was chosen because it was at the upper end of the 
calculated sample sizes (see Appendix 1). Epi-info V6 (Division of Surveillance and 
Epidemiology, Epidemiology Program Office, Centre for Disease Control and 
Prevention, Atlanta, Georgia) was used for data recording and generation of z-scores 
from NCHS reference data. All anthropometric data were dual entered with a 
validation performed between the two entry records and against the hard copy of the 
data at the end of the data gathering period.
Data were then transferred to SPSS v8.0 for analysis (Statistical Product and Service 
Solutions Inc, Chicago, USA). Differences between groups were compared using t- 
tests or one-way analysis of variance for quantitative variables with approximately
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normal distributions, Mann-Whitney or Kmskal-Wallis tests for ordinal variables, and 
chi-squared tests for categorized variables, with Yates correction used for 2x2 tables. 
The three treatment groups were also treated as ordinal for outcomes after discharge, 
and trends were tested using Pearson or Spearman correlations as appropriate. 
Analysis of covariance was used to test differences in quantitative outcomes between 
groups after adjusting for other factors. Univariate regression analysis was used to 
identify predictors of change in e.g. HAZ score and then construct a regression model 
to explain change.
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Chapter 3: Results
3.1. Initial Anthropometry
141 subjects were recruited and baseline characteristics were similar between 
treatment groups with no significant differences found (table 2). The average age at 
recruitment was 15.5 months with 57% of the subjects under 1 year old. The subjects 
were both severely wasted and very severely stunted with an average initial WHZ of - 
2.66, WAZ of -4.56 and HAZ of -3.89. Numbers of children with kwashiorkor (10- 
15%), marasmic kwashiorkor (25-30%) and marasmus (55-60%) were equally 
distributed.
16 subjects either self-discharged as in-patients (n=6), most commonly due to social 
pressures on the subject’s mother preventing her from completing the in-patient 
phase, or were lost to follow-up (n=10) (Table 3). A follow-up worker visited each 
dwelling at least twice after a subject defaulted from follow-up. All defaulters could 
not be found at their homes and information sought from neighbours suggested that 
internal migration within Bangladesh, and usually back to ancestral family villages, 
was responsible.
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Table 2: Characteristics of children at entry into trial. Figures shown are mean +/- 
or number of patients.
Zinc Group 1.5 /  Placebo 6.0 / Placebo 6 .0 /6 .0
Number 49 49 43
Age (months) 15.5+/-8.7 15.0+/-9.0 16.3+/-8.6
Weight fo r  Age Z score -4.47+/-0.91 -4.56+/-0.98 -4.66+/-0.86
Weight fo r  Height Z score -2.56+/-0.97 -2.73+/-0.90 -2.71+/-0.93
Height fo r  Age Z score -3.89+/-1.3 -3.79+/-1.4 -3.98+/-1.45
Malnutrition: M 29 27 26
: M/K 15 14 11
: K 5 7 6
Admission to 
Recruitment (days)
2.5+/-1.5 3.5+/-2.2 2.7+/-1.8
M is marasmus, M/K is marasmic kwashiorkor and K is kwashiorkor.
Table 3: Outcome and mortality rates in the three zinc supplementation regimens
Outcome
Regimen Completed
Protocol
In-patient
Death
Out-patient
Death
Self-Discharge / 
Lost to follow-up
1.5/Plac 43 2 0 4 49
6.0 /  Plac 38 5 3 3 49
6.0/6 .0 25 6 3 9 43
106 13 6 16 141
* A comparison of in-patient and out-patient combined death rate between those 
children who received 6.0mg/kg/d zinc initially (regimens 2 & 3) and those who 
received 1.5mg/kg/d initially (regimen 1) demonstrates a Yates corrected chi-squared 
value of risk of death of 4.52 (p=0.03) (95% confidence interval for relative risk of
1.09-18.8).
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3.2. Mortality
There was an excess of deaths in the groups receiving 6.0mg/kg/day zinc as in­
patients (table 3). This trend was identified in an interim analysis of the first 100 
subjects, and enrollment was suspended after 141 recruits. When supplementation 
regimens 2 and 3 were combined and death rates compared throughout the entire 90 
day study period against regimen 1, a Yates corrected chi-squared value of risk of 
death was significant at 4.52 (p=0.03) with exposure to 6.0mg/kg/day as against 
1.5mg/kg/day initially, and a 95% confidence interval for relative risk of 1.09 - 18.8.
Cause of death was defined by a clinician’s impression (Table 4). Most deaths were 
sepsis-related and 13 out of the 19 deaths occurred as in-patients.
I next considered those children who died in association with exposure to 
6.0mg/kg/day initially and tried to identify factors that could possibly predict for 
increased risk of death (table 5). Combining regimens 2 and 3 I then compared death 
rates within subgroups depending on whether a specific possible prognostic factor for 
death was present or absent. Prognostic factors considered were age, degree of 
wasting and stunting, severity of initial illness, and type of malnutrition, but none of 
these factors was found to predict death in association with exposure to the higher 
initial dose of zinc (Table 5).
Due to the increased infection related mortality associated with high dose zinc 
supplementation, I will next describe the inflammatory status, plasma zinc and copper 
status of these children. High dose zinc supplementation can produce a copper 
deficiency (see discussion) that can be related to an immunodeficiency.
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Table 4: Clinical impression of cause of death of individual children.
Subject Regimen Details of Death Day
1 028 1 Sepsis and diarrhoea 7
2 066 1 Sepsis and ARI symptoms 10
3 008 2 Sepsis and ARI symptoms 8
4 033 2 Sepsis - no localizing symptoms O.P.
5 039 2 Sepsis - ARI and diarrhoea O.P.
6 048 2 Sepsis and diarrhoea 22
7 056 2 Sepsis - Disseminated intravascular coagulation 2
8 062 2 Sepsis and diarrhoea 7
9 118 2 ? Tubercular meningitis 8
10 134 2 Poor weight gain as OP / ARI - refused re-admission O.P.
11 024 3 Sepsis - no localizing symptoms
12 067 3 Sepsis and severe anemia 10
13 068 3 Acute liver failure -? pyrazinimide toxicity O.P.
14 079 3 Aspirated + cardiac arrest - preceding diarrhoea 20
15 087 3 Sepsis - ARI and severe anemia 3
16 088 3 Failure to progress as O.P, developed oedema and sepsis O.P.
17 103 3 Sepsis - Diarrhoea and ARI 6
18 113 3 ? O.P.
19 125 3 ? Abdominal Tuberculosis - Aspirated and cardiac arrest 8
Note : O.P = Out-patient and ARI = Acute respiratory infection
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Table 5: Prognostic factors for death among those exposed to higher dosage 
zinc regimens initially.
Death rate when factor
Present Absent
Age 12 months or less 8/52 9/40
Weight fo r Age <45% median 4/24 (17) 13/68 (19)
Weight fo r Height < 70% median 9/43 (21) 8/49 (16)
Height fo r  Age <85%  median 9/42 (21) 8/50 (16)
Admission - Recruitment >3days 5/23 (22) 12/63 (19)
Diarrhoea at Adm : any 9/50 (18) 7/33 (17)
: persistent 5/22 (23) 11/68 (16)
Malnutrition typ e : Marasmus 9/53 (17) 8/38 (21)
: Marasmic Kwashiorkor 6/25 (24) 11/66(17)
: Kwashiorkor 2/13 (15) 15/78 (19)
Mother’s Education < 2yrs 10/60(15) 8/32 (25)
Note : Adm - admission
Figures are shown as number of deaths / total number (%) where individual factor is 
present or absent. The combined denominator figure for individual risk factors should 
equal 92 (i.e. total number of children randomised to Regimens 2 & 3). In some cases 
the total figure is below 92 where data collection errors prevented the assignment of 
individual children to ‘present* or ‘absent* groups.
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3.3. Inflammation and plasma zinc & copper levels
Table 6 shows the mean (and standard deviation) plasma zinc, copper and C-reactive 
protein (CRP) concentrations for the children in each regimen for days 1,15 and 30. 
Table 7 shows the differences in zinc, copper and CRP between regimens. Both mean 
zinc (normal range 12-18micromol/l) and copper (normal range 10-22 micromol/1) 
were on the lower limit of normal on day 1 and there were no significant inter- 
regimen differences.
Mean plasma zinc concentrations of regimens 2 & 3 on day 15 were significantly 
different from those of regimen 1. Children in regimens 2 & 3 received 6mg/kg zinc 
until day 15 as opposed those children in regimen 1 who received 1.5 mg/kg. Day 30 
zinc concentrations had again increased in regimen 3 and were significantly higher 
than those in regimens 2 or 1, which had declined to below day 1 concentrations. 
Regimen 3 children had continued high dose supplementation onto day 30 whilst both 
regimen 1 and 2 children had ceased supplementation at day 15.
Plasma copper concentrations rose consistently throughout the 30 day period and 
there were no significant differences between any regimen at any day. Both zinc and 
copper concentrations are illustrated in fig 1.
Mean CRP concentrations and number of abnormal (defined as above 10 mg/1) 
measurements decreased over the 30 day period (table 6). There were no significant 
differences initially between groups (table 7) but combining regimens 2 & 3 and
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comparing them against regimen 1 at day 15, there was a significant difference in 
number of abnormal CRP measurements (table 9) but not in mean CRP.
There were no significant differences in either plasma zinc or copper concentrations 
between survivors and non-survivors but there were significant differences in initial 
CRP concentrations (table 8).
There was a significant association between risk of death and elevated CRP at Day 1 
(table 9).
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Table 6: Mean (standard deviation) plasma zinc (micromol/1), copper (micromol/1) 
and CRP (mg/1) concentrations and percentage of CRP measurements greater than 10 
for each regimen on specified days.
Dayl Day 15 Day 30
Regimen 1 2 3 1 2 3 1 2 3
(n) n=49 n=47 n=43 n=40 n=41 n=34 n=40 n=39 n=30
Zinc 12.28 13.19 12.16 13.7 16.19 18.5 12.02 10.64 19.63
(7.05) (4.94) (4.8) (5.48) (6.11) (8.86) (5.67) (3.07) (10.73)
Copper 16.19 13.71 13.19 18.5 17.12 17.78 21.82 21.47 19.1
(7.07) (5.3) (4.05) (6.16) (6.06) (5.95) (5.71) (6.93) (5.29)
CRP 15.65 12.11 18.63 2.79 9.97 5.03 4.36 6.43 5.5
(24.7) (15.99) (27.5) (2.99) (21.29) (8.07) (7.06) (12.02) (12.36)
CRP>10 34.6 36 37 2.5 19.5 21.4 12.1 12.8 13.3
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Table 7: Comparison of mean plasma zinc, copper and CRP concentrations between 
regimens on specified days.
Day 1* Day 15** Day 30**
Regimen 1 / 2&3 Regimens 1/2 Regimens 2/3
Zn p=0.23 p=0.002 p=0.22 p=0.000
Copper p=0.14 p=0.41 p=0.68 p=0.2
CRP p=0.93 p=0.23 p=0.3 p=0.53
* Kruskal-Wallis 1-Way Anova 
** Mann Whitney U 
CRP is C reactive protein
Table 8: Initial zinc, copper and CRP concentrations in those children who died 
compared with survivors.
Survivors Deaths Differences
n=  122 n=  19 between groups
Day 1: mean (s.d.) zinc 12.7 (5.77) 10.7 (3.01) p=0.28
Day 1: mean (s.d.) copper 14.4 (5.99) 14.3 (5.18) p=0.48
Day 1: mean (s.d.) CRP 13.9 (22.04) 25.1 (28.29) p=0.008
* Kruskal-Wallis H
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Table 9: Chi-square contingency table of days 1 & 15 C reactive protein concentration 
compared to regimen and occurrence of death.
Regimen Death Chi- P
Sq value
1 2 3 2&3 No Yes
D1 CRP Normal 32 31 27
High 17 17 16 1.95 0.74
D15CRP Normal 39 61
High 1 14 6.01 0.049
D1 CRP Normal 85 5
High 37 13 17.99 0.000
3.4. Ponderal, linear & knemometric growth
There were no significant differences in change of any anthropometric variable 
between regimens (table 10). Over the 90 days, significant catch-up growth was 
achieved with an average intragroup improvement of WHZ score of 1.54 to 1.67 and 
in HAZ score of 0.44 to 0.49 units. Lower leg length grew on average 1.03 to 1.04 cm 
in the 90 days (table 10).
Neither employing an initially higher dosage (regimen 2) nor prolonging 
supplementation into the outpatient phase (regimen 3) had any significant effect on 
promoting further weight gain. Initial WHZ score correlated significantly negatively 
and inpatient WHZ score change correlated significantly positively with subsequent 
ponderal growth over both 45 and 90 days (table 11). Over 40% of the children were 
admitted with nutritional oedema that would have influenced changes in 
anthropometric indices during the inpatient period. Correlations between changes in 
inpatient anthropometric indices and subsequent changes over both 45 and 90 days 
were thus repeated in only those children with marasmus. The correlations noted 
above in the group as a whole were demonstrable in this smaller subgroup.
Day 1 measurements and change in measurements are compared for 3 age groups in 
table 12. Those in the 6-12 month age group were less wasted initially and had 
significantly better linear growth in the second half of the study.
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Table 10: Change in anthropometric variables during 90 days of study protocol for 
each supplementation group.
95% C.I. fo r  mean 
difference
1 .5 /P lac
n=43
6 .0 /P lac  
n—38
6 .0 /6 .0  
n=25
6.0/Plac- 
1.5/Plac
6.0/6.0- 
6.0/Pl ac
WAZ 1.35+/-0.69 1.51+/-0.65 1.45+/-0.66 -0.27, +0.52 -0.47, +0.38
WHZ 1.54+/-0.93 1.67+/-0.78 1.62+/-0.86 -0.14, +0.46 -0.39,+0.27
HAZ 0.44+/-0.32 0.48+/-0.38 0.49+/-0.27 -0.11,+0.2 -0.17,+0.18
LLL 1.04+/-0.48 1.03+/-0.49 1.03+/-0.33 -0.23, +0.2 -0.22, +0.22
SFT 3.06+/-1.94 3.63+/-1.87 3.61+/-1.86 -0.29,+1.43 -0.97, +0.94
M.U.A.C 1.66+/-1.4 1.98+/-1.17 1.9+/-1.3 8 -0.26, +0.89 -0.72, +0.57
Note : WAZ - Weight for Age Z score, WHZ - Weight for Height Z score, HAZ - 
Height £>r Age Z score, SFT - Skinfold thickness’, M.U.A.C - mid upper arm 
circumference, C.I.- confidence intervals
Figures ihown are mean+/- sd. Knemometry (LLL) and MUAC are in cm whilst SFT 
is in mm
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Table 11: Correlation between initial and inpatient change in anthropometric indices 
versus total change.
Linear growth Knemometric growth Ponderal Growth
Dl/45
HAZA
Dl/90
HAZA
Dl/45
LLLA
Dl/90
LLLA
Dl/45
WHZA
Dl/90
WHZA
D1WHZ 0.33 *** 0.36 *** 0.15 0.2* -0.25 * -0.28 **
D1 HAZ -0.17 0.03 -0.13 -0.07 -0.18 -0.09
D1 LLL -0.1 -0.2* -0.12 -0.13 -0.01 -0.00
Dl/15 WHZA 0.1 -0.03 0.47 *** 0.25* 0.51 *** 0.27 **
MD1/15WHZA 0.22 0.16 0.41 ** 0.27* 0.33 ** 0.11
Dl/15 HAZA 0.28 ** 0.24* -0.06 -0.05 -0.16 -0.12
MD1/15 HAZA 0.36 ** 0.16 -0.08 -0.002 -0.03 -0.04
Dl/15 LLLA 0.07 -0.06 0.64 *** 0.25 * 0.21 * -0.03
MD1/15LLLA 0.22 0.12 0.61 *** 0.33 * 0.21 -0.08
Knemometric growth is LLL (lower leg length)A.
D ‘x’ ‘anthropometric variable’ : specified anthropometric reading on specified day 
D ‘x/y’ ‘anthropometric variable’ A : change in specified anthropometric variable 
between specified days
MD‘x/y’ ‘anthropometric variable’ : change in specified anthropometric variable 
between specified days in those children with marasmus only 
p<0.05, **p<0.01, ***p<0.001 
Note: Day 1/15, Day 1/45 and Day 1/90 are not independent variables.
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Table 12: Baseline anthropometry and knemometry (mean (SD and number of 
subjects)), type of malnutrition and growth (mean change (SD and number of 
subjects)) in 3 age groups of study subjects.
Age Group 6-12 months 13-24 months 25-36 months
Marasmus 47 24 11
MarasmicKwashiorkor 21 12 8
Kwashiorkor 12 5 1
Day 1 WHZ T -2.3 (0.9, n=80) -3.0 (0.9, n=41) -3.1(0.7, n=20)
Day 1 HAZ -3.6 (1.1, n=80) -4.1 (1.6, n=41) -3.9 (1.1, n=20)
Day 1 LLL 15.8 (1.3, n=80) 18.0 (1.6, n=41) 20.7 (1.7, n=20)
Daysl/45 WHZA 0.99 (0.8, n=65) 1.51 (0.6, n=29) 1.16 (0.9, n=17)
Days 1/45 HAZ A 0.18 (0.2, n=65) 0.12 (0.1, n=29) 0.19 (0.2, n=17)
Days 1/45 LLL A 0.46 (0.3, n=65) 0.56 (0.3, n=29) 0.47 (0.3, n=17)
Days 45/90 WHZ A 0.53 (0.7, n=61) 0.3 (0.7, n=26) 0.33 (0.5, n=16)
Days 45/90 HAZ A* 0.38 (0.3, n=61) 0.22 (0.2, n=26) 0.19 (0.2, n=16)
Days 45/90 LLL A 0.58 (0.3, n=61) 0.45 (0.4, n=26) 0.53 (0.4, n=16)
Day 90 WHZs -0.74(1.1, n=61) -1.28(1.1, n=26) -1.63(0.8, n=16)
Day 90 HAZ “ -2.99(1.0, n=61) -3.93(1.8, n=26) -3.7 (1.0, n=16)
Day 90 LLL1 16.9 (1.2, n=61) 18.6 (1.9, n=26) 21.6 (1.5, n=16)
Days ‘x’/’y’ is day y - day x 
t  ANOVA between age groups p=0.000 
X ANOVA between age groups p=0.003 
§ Paired samples t test between day 1 and 90 p=0.000
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f t  Paired samples t test between day 1 and 90 p=0.000 
t t t  Paired samples t test between day 1 and 90 p=0.000
Linear catch up growth was also demonstrated (table 10). Again there were no 
significant differences between regimens with most catch-up growth occurring during 
the second half of the study. Knemometric growth (table 10) occurred mostly in the 
second half of the study and there were no significant differences between regimens.
To examine the relationship between ponderal and linear growth (fig 2) I plotted 
linear growth over the subsequent 30 days against initial WHZ score for all children at 
every time point. This demonstrated a strong correlation between WHZ score and 
subsequent linear growth [r = 0.3, p<0.001]. Linear growth occurred in the presence 
of severe wasting and no threshold could be identified. Initial WHZ score correlated 
significantly with subsequent linear growth over both 45 and 90 days whereas HAZ 
score did not. Inpatient change in HAZ score but not in WHZ or knemometric length 
correlated strongly with subsequent change in HAZ score over both 45 and 90 days 
(table 11) however inpatient change in HAZ score is not independent of total change 
over 90 days.
Knemometric growth also occurred in the presence of severe wasting but correlated 
poorly with initial WHZ score (table 11). It correlated well with ponderal indices in 
the first half of the study and only correlated with linear growth from day 45 onwards 
(table 13).
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Figure 2: Mean change in HAZ score in the subsequent 30 days plotted versus initial 
WHZ score at that time for data from Days 1, 15, 30, 45, & 60. (r=0.3, p<0.001)
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Table 13: Correlation coefficients between changes in knemometry versus changes 
other anthropometric indices between Day 1 and subsequent measurement days
Day T.S.F.T. M.U.A.C. WHZ score HAZ score
15 0.32 *** 0.44*** 0.49*** -0.14
30 0.31 ** 0.34*** 0.51*** 0.16
45 0.3 ** 0.38*** 0.55*** 0.19*
60 0.41*** 0.43*** 0.56*** 0.49***
90 0.37*** 0.39*** 0.48*** 0.47***
T.S.F.T = triceps skin fold thickness 
M.U.A.C = mid upper arm circumference 
* p<0.05
** p<0.01 
*** p<0.001
Growth is predominately ponderal initially in severely malnourished children and 
linear growth occurs when WHZ score approaches the median NCHS reference (fig 
2). Univariate regression analysis was used to identify predictors of linear growth and 
then to construct a linear regression model. Only maternal height and day 1 WHZ 
score predicted in our model and only accounted for 20% of total variance (Tables 14 
& 15).
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Figure 3: WHZ and HAZ score increase over 30 days against initial WHZ score (to 
nearest 0.5 z score) for all time points.
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Table 14: Univariate regression analysis for change in HAZ score over 90 days
Sex y = 0.45+ 0.013 (-0.12, 0.14) x p = 0.85
Type of malnutrition y = 0.39+ 0.05 (-0.04, 0.14) x p = 0.253
Age y = 0.62 -  0.01 (-0.02, -0.003) x p = 0.008
WHZ day 1 y = 0.79+ 0.12 (0.06,0.19) x p <  0.0001
HAZ day 1 y = 0.5+ 0.01 (-0.04,0.06) x p = 0.73
WHZ A 1/90 days y = 0.39 + 0.05 (-0.02, 0.13) x p = 0.17
Maternal height y = -1 .96+1.65 (2.7,0.01) x p = 0.009
Maternal B.M.I. y = 0.11+0.02 (-0.01, 0.03) x p = 0.25
Table 15: Linear regression model of change in HAZ score over 90 days
Std error
Constant -1.49 0.88
WHZ score day 1 0.122 0.036 p = 0.001
Maternal height 1.54 0.59 p = 0.01
Sum of squares df mean square
Regression 1.66 4 0.83 p<0.0001
Residual 6.88 70 0.09
Total 8.5 74
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3.5. Collagen turnover and insulin-like growth factor axis
There were significant changes in all indices of collagen formation and degradation 
and growth factor activity over the first 15 days (table 16 & fig 4) with inter regimen 
differences demonstrable only in IGF1 (days 1,15) and BAP (day 30).
Compared to similarly aged but well nourished European children severely 
malnourished Bangladeshi children had low insulin like growth factor 1(IGF1) and 
insulin like growth factor binding protein 3 (IGFBP3) with high insulin like growth 
factor binding protein 2 (IGFBP2) measurements. They also had low bone alkaline 
phosphatase (BAP) and variable but high collagen type 1 cross linked telopeptide 
(1CTP) (fig 4) measurements. On rehabilitation BAP, procollagen type 1 C terminal 
propeptide (PICP), procollagen type 3 N terminal propeptide (P3NP), pyridinoline 
(PYD), deoxypyridinoline (DPD), IGF1 and IGFBP3 measurements all increased 
associated with a decrease in IGFBP2 and 1CTP measurements (table 16 & fig 4). 
There were strong positive correlations among BAP, PI CP, IGF1 and IGFBP3 at 
every time point (p<0.01), and between 1CTP and IGFBP2 at every time point 
(p<0.01] (tables 18-20). Conversely IGFBP2 was negatively correlated with PI CP, 
IGF1 and IGFBP3 at every time point (p<0.01) and with BAP on days 15 and 30 
(p<0.05> 1CTP was negatively correlated with PI CP, IGF1 and IGFBP3 on 
admission (p<0.05). PYD and DPD did not correlate with any other biochemical 
marker ct any time point including 1CTP but did correlate with each other at every 
time poiit (p<0.01).
Change in PI CP and P3NP correlated significantly with change in IGF1 and IGFBP3 
(table 21). Change in BAP correlated significantly with change in IGF1 and PI CP.
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Change in PYD correlated significantly with changes in IGF1, IGFBP3 and P3NP. 
Change in IGFBP2 did not correlate with change in collagen formation, degradation 
or bone osteoblastic activity (table 21).
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Table 16 (a): Collagen synthesis, degradation and osteoblastic activity.
1.5/P lac 6.0/P lac
Day 1 15 30 1 15 30 1
P1CP 392.5
(211.3)
805.5
(428.4)
948.1
(437.7)
374.2
(330.9)
739.2
(495.8)
916.2
(557.9)
352.5
(162.1)
P3NP 8.6
(5.5)
20.9
(11.4)
22.8
(12.8)
7.1
(5.0)
18.4
(12.8)
23.0
(21.1)
8.5
(7.3)
BAP 39.8
(20.3)
59.8
(48.6)
78.6
(38.6)
37.5
(17.5)
44.6
(15.1)
59.4
(30.5)
35.6
(17.8)
PYD 484.40
(328.8)
689.58
(466)
777.74
(447.7)
442.29
(282.8)
671.51
(455.6)
711.86
(377.8)
453.67
(289.2)
DPD 86.0
(75.0)
125.6
(97.2)
130.5
(80.7)
75.8
(75.3)
113.5
(94.5)
121.8
(77.4)
80.5
(47.0)
Table 16 (b): Insulin like growth factor axis activity
1.5/P lac 6 .0 /P lac
Day 1 15 30 1 15 30 1
IGF1 9.94
(7.62)
34.27
(25.9)
36.33
(34.29)
6.45
(4.55)
20.24
(16.54)
27.59
(23.61)
7.88
(7.62)
IGFBP2 1712.41
(777.93)
1194.27
(795.9)
1022.77
(442.1)
2157.76
(1378.1)
1434.48
(788.4)
1334.9
(888.6)
1794.57
(1004.8)
IGFBP3 737.9
(461.2)
1749.64
(993.55)
1732.1
(992.9)
657.16
(352.87)
1480.57
(847.1)
1620.8
(959.3)
745.31
(526.97)
Figure 4: Collagen, bone and growth factor markers (mean and 95% C.I.) vs. time. 
Data are shown separately for the 3 regimens. Reference data for age matched well 
nourished European children are shown as dashed lines, (a) PI CP, (b) P3NP, (c) BAP, 
(d) 1CTP, (e) PYD, (f) DPD, (g) IGF1, (h) IGFBP3, (i) IGFBP2.
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Fig 4b: Collagen, bone and growth factor markers (mean and 95% C.I.) vs. time. Data
are shown separately for the 3 regimens. Reference data for age matched well
nourished European children are shown as dashed lines
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Fig 4c: Collagen, bone and growth factor markers (mean and 95% C.I.) vs. time. Data
are shown separately for the 3 regimens. Reference data for age matched well
nourished European children are shown as dashed lines
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Fig 4d: Collagen, bone and growth factor markers (mean and 95% C.I.) vs. time. Data
are shown separately for the 3 regimens. Reference data for age matched well
nourished European children are shown as dashed lines
(d) ICTP
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Fig 4e: Collagen, bone and growth factor markers (mean and 95% C.I.) vs. time. Data
are shown separately for the 3 regimens. Reference data for age matched well
nourished European children are shown as dashed lines
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Fig 4f: Collagen, bone and growth factor markers (mean and 95% C.I.) vs. time. Data
are shown separately for the 3 regimens. Reference data for age matched well
nourished European children are shown as dashed lines
(f) DPD
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Fig 4g: Collagen, bone and growth factor markers (mean and 95% C.I.) vs. time. Data 
are shown separately for the 3 regimens. Reference data for age matched well 
nourished European children are shown as dashed lines. Note that upper limit of IGF 1 
for European children is 195.9pg/l.
(g) ig f i
ZL
20 ■
43 39 32N 49 49 42 44 42 35
15
Day
30
REGIMEN
I
□ 1
1
O 2
■■*
O  3
101
Fig 4h: Collagen, bone and growth factor markers (mean and 95% C.I.) vs. time. Data
are shown separately for the 3 regimens. Reference data for age matched well
nourished European children are shown as dashed lines
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Fig 4i: Collagen, bone and growth factor markers (mean and 95% C.I.) vs. time. Data
are shown separately for the 3 regimens. Reference data for age matched well
nourished European children are shown as dashed lines
(i) IGFBP2
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Table 17: p values of differences between inter-regimen means on days 1,15 & 30 
and p values of differences between means on days 1 and 15 and between days 15 and 
30
D1
Regimen
D15
Regimen
D30
Regimen
1/15 15/30
P1CP 0.19 0.52 0.55 0.000 0.002
P3NP 0.18 0.30 0.62 0.000 0.040
BAP 0.78 0.39 0.03 0.000 0.000
PYD 0.76 0.07 0.73 0.000 0.012
DPD 0.15 0.14 0.62 0.000 0.041
IGF1 0.04 0.04 0.13 0.000 0.906
IGFBP2 0.15 0.07 0.34 0.000 0.039
IGFBP3 0.78 0.42 0.89 0.000 0.643
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Table 18: Correlation between indices on Day 1
P1CP P3NP ICTP BAP IGF1 IGFBP3 IGFBP2
P1CP Pearson Correlat 
Sig. (2-tailed)
1.000 .558*
.000
-.125
.143
.253*’
.003
.233*
.006
.265*
.002
-.171*
.043
P3NP Pearson Correlal 
Sig. (2-tailed)
.558*
.000
1.000 .043
.618
.226*
.007
.268*
.001
.190*
.025
-.124
.145
1CTP Pearson Correlal 
Sig. (2-tailed)
-.125
.143
.043
.618
1.000 .107
.213
-.165
.053
-.206*
.015
.204*
.016
BAP Pearson Correlat 
Sig. (2-tailed)
.253*
.003
.226*
.007
.107
.213
1.000 .083
.334
.215*
.011
-.114
.181
IGF1 Pearson Correlat 
Sig. (2-tailed)
.233*
.006
.268*
.001
-.165
.053
.083
.334
1.000 .725*
.000
-.260*
.002
IGFBPC Pearson Correlal 
Sig. (2-tailed)
.265*
.002
.190*
.025
-.206*
.015
.215*
.011
.725*
.000
1.000 -.275*
.001
IGFBPi Pearson Correlal 
Sig. (2-tailed)
-.171*
.043
-.124
.145
.204*
.016
-.114
.181
-.260*
.002
-.275*
.001
1.000
PYD Pearson Correlal 
Sig. (2-tailed)
.165
.065
.219*
.014
.134
.136
.280*’
.002
.214*
.016
.201*
.024
-.037
.681
DPD Pearson Correlat 
Sig. (2-tailed)
.308*
.001
.279*
.002
-.012
.898
.109
.228
.262*
.003
.181*
.044
-.003
.973
"•Correlation is significant at the 0.01 level (2-tailed).
*• Correlation is significant at the 0.05 level (2-tailed).
Table 19: Correlations between indices on Day 15
P1CP P3NP ICTP BAP IGF1 IGFBP3 IGFB
P1CP Pearson Correlatic 1.000 .627*’ -.066 .350*’ .266*’ .307*’
Sig. (2-tailed) .000 .471 .000 .003 .001
P3NP Pearson Correlatic .627*’ 1.000 -.064 .242*’ .426*’ .410*’ -.£
Sig. (2-tailed) .000 .490 .008 .000 .000
ICTP Pearson Correlatic -.066 -.064 1.000 -.025 -.173 -.196*
Sig. (2-tailed) .471 .490 .789 .058 .032
BAP Pearson Correlatic .350*’ .242* -.025 1.000 .268*’ .268*’ -.2
Sig. (2-tailed) .000 .008 .789 .003 .003
IGF1 Pearson Correlatic .266*’ .426*’ -.173 .268*’ 1.000 .807*’ -.£
Sig. (2-tailed) .003 .000 .058 .003 .000
GFBP3 Pearson Correlatic .307*’ .410*’ -.196* .268*’ .807*’ 1.000 -.£
Sig. (2-tailed) .001 .000 .032 .003 .000
IGFBP2 Pearson Correlatic -.314*’ -.318*' .460* -.224* -.541*’ -.529*’ 1.C
Sig. (2-tailed) .000 .000 .000 .013 .000 .000
PYD Pearson Correlatic .214* .294*1 .027 .145 .110 .182 -.(
Sig. (2-tailed) .021 .001 .776 .120 .242 .051
DPD Pearson Correlatic .108 .212* -.038 .115 .100 .073 -.(
Sig. (2-tailed) .260 .027 .693 .231 .296 .445
**• Correlation is significant at the 0.01 level (2-tailed).
*• Correlation is significant at the 0.05 level (2-tailed).
Table 20: Correlations between indices on Day 30
P1CP P3NP ITCP BAP IGF1 IGFBP3 IGF
P1 CP Pearson Correlation 
Sig. (2-tailed)
1.000 .733**
.000
.116
.224
.356**
.000
.294**
.002
.314**
.001
P3NP Pearson Correlation 
Sig. (2-tailed)
.733**
.000
1.000 .146
.126
.256**
.007
.328**
.000
.387**
.000
ITCP Pearson Correlation 
Sig. (2-tailed)
.116
.224
.146
.126
1.000 .009
.925
.070
.466
.082
.388
BAP Pearson Correlation 
Sig. (2-tailed)
.356**
.000
.256**
.007
.009
.925
1.000 .190*
.046
.156
.101
IGF1 Pearson Correlation 
Sig. (2-tailed)
.294**
.002
.328**
.000
.070
.466
.190*
.046
1.000 .796**
.000
IGFBP3 Pearson Correlation 
Sig. (2-tailed)
.314*’
.001
.387**
.000
.082
.388
.156
.101
.796**
.000
1.000
IGFBP2 Pearson Correlation 
Sig. (2-tailed)
-.243**
.009
-.208*
.027
.546**
.000
-.191*
.044
-.423**
.000
-.423**
.000
PYD Pearson Correlation 
Sig. (2-tailed)
.187*
.048
.261**
.005
.056
.560
.126
.188
.438**
.000
.427**
.000
DPD Pearson Correlation 
Sig. (2-tailed)
.132
.164
.192*
.043
-.051
.598
.144
.134
.079
.407
.183
.053
**• Correlation is significant at the 0.01 level (2-tailed).
*• Correlation is significant at the 0.05 level (2-tailed).
Table 21: Correlations between change in biochemical indices over 30 days.
P1CP
P3NP +0.37** P3NP
BAP +0.22** +0.11 BAP
PYD +0.07 +0.18** +0.12 PYD
DPD +0.07 +0.10 +0.11 +0.45** DPD
ICTP -0.03 -0.06 +0.15* +0.00 -0.05 ICTP
IGF1 +0.26** +0.44** +0.17** +0.21** +0.04 -0.02 IGF1
IGFBP3 -0.21** +0.34** +0.12 +0.19** +0.06 -0.14* +0.58** -
IGFBP2 -0.20* -0.08 -0.00 -0.02 -0.08 +0.11 -0.18**
Change in PI CP and P3NP over 30 days correlated with change in WHZ, HAZ and 
knemometric length over 30 days and change in WHZ score (less so), change in HAZ 
score and knemometric length (more so) over 90 days. Change in IGF1 over 30 days 
correlated with ponderal growth and knemometric growth but not linear growth over 
90 days. Change in IGFBP3 levels over 30 days correlated with linear and 
knemometric growth over 90. Change in BAP levels over 30 days correlated with 
knemometric growth over 90. Change in collagen degradation markers correlated 
poorly with growth with only change in ICTP correlating with knemometric growth 
over 30 days (table 22).
Kwashiorkor and marasmus were both associated with low IGF1 and IGFBP3 and 
elevated IGFBP2 levels. IGF1 and IGFBP3 levels increased with rehabilitation and 
IGFBP2 levels fell with the only differences between marasmic and kwashiorkor 
children noted in day 15 and 30 IGFBP3 levels (p<0.05). There was no difference in 
change in PI CP, P3NP, BAP, ICTP, IGF1, IGFBP3 or IGFBP2 between marasmic 
and kwashiorkor children but there were differences in day 1 PI CP and P3NP. When 
differences in day 1 HAZ and WHZ were allowed for the differences in days 15 & 30 
IGFBP3 and day 1 PI CP respectively were non-significant. Even accounting for 
differences in initial anthropometry difference in day 1 P3NP remained (p=0.001).
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Table 22: Correlation between change in anthropometric variables between either days 1 to 30 (1/30) or cL 
biochemical variable between days 1 and 30
P1CP P3NP BAP PYD DPD ICTP IGF1
1/30WHZ +0.21** +0.32** +0.23** +0.06 -0.06 +0.10 +0.31**
1/90WHZ +0.14* +0.17* +0.10 +0.07 +0/02 -0.11 +0.15*
1/30HAZ +0.15* +0.16* -0.01 +0.04 +0.04 +0.03 +0.06
1/90HAZ +0.21** +0.25** +0.14 +0.04 -0.01 +0.02 +0.14
1/30LLL +0.14* 0.25** +0.14* +0.01 -0.07 +0.19** +0.19**
1/90LLL +0.21** +0.33** +0.19** +0.09 +0.03 +0.08 +0.28**
* significant at 0.05 level
** significant at 0.01 level
Chapter 4: Discussion
The aims of this study were threefold. To describe the patterns of and relationship 
between ponderal and linear catch-up growth in the recovery phase from severe 
malnutrition. To describe bone, soft tissue and collagen turnover during this phase and 
to assess the effects of three different regimens of zinc supplementation on the above 
processes and thus the optimal dosage range for severely malnourished children.
This study has shown that in severely malnourished Bangladeshi children there were 
no differences in anthropometric or biochemical marker responses among the 3 zinc 
regimens. 141 children were recruited making this the largest zinc intervention study 
to date in this group. Significant catch-up growth was achieved with an average 
intragroup improvement of WHZ score of 1.54 to 1.67 and in HAZ score of 0.44 to 
0.49 units. Mortality differences between the 3 groups of children became evident on 
analysis and were an unexpected finding. Linear growth was significantly associated 
with initial WHZ but occurred in the presence of severe wasting. Bone remodelling 
and soft tissue turnover commenced early and was associated with a fall in IGFBP2 
and an increase in IGF1 and IGFBP3.
Despite the evident confusion in the literature on the zinc requirement of the severely 
malnourished child this study is the only one to date to compare different zinc 
supplementation regimens in these children. The recommended dietary allowance of 
zinc for a one-year-old is 5mg/day (National Academy of Sciences 1989). A child 
recovering from severe protein energy malnutrition however is already deficient and 
in need of a higher dietary intake during the recovery process due to often spectacular 
rates of weight gain. Golden et al (Golden 1992; Golden 1981) have demonstrated
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that zinc influences rate of weight gain as well as the ratio of lean to adipose tissue 
deposited by comparing the energy cost of tissue deposition in marasmic children fed 
low zinc soya based feeds with those fed higher zinc containing milk feeds. Further 
they demonstrated that zinc supplementation of marasmic children resulted in a 
greater net absorption of nitrogen and a higher rate of protein turnover, as estimated 
from urinary ammonia 15N enrichment after oral (15N) glycine. They concluded that 
additional zinc affected the composition of newly synthesised tissue and intermediary 
nitrogen metabolism.
Both the bioavailability of dietary zinc and the continuing losses in these children 
(due to the high prevalence of diarrhoea) also contribute to difficulty in estimating 
requirements in this group.
There is approximately 30mg zinc/g fat free mass in adult men however only those 
zinc pools in the liver and plasma (5% of total body zinc) are readily accessible. The 
much larger zinc pools of muscle and bone are only available in episodes of 
catabolism. During episodes of deprivation zinc homeostasis depends on the liver and 
intestine with an increase in intestinal absorption and a decrease pancreatico-biliary 
secretion.
Simmer et al (Simmer 1990) measured the daily intake of zinc in breast fed 
Bangladeshi infants aged 1,2, 6, 9, and 12 months and found them to be between 10 
to 30% of the National Academy of Sciences recommended dietary allowances. 
Important dietary sources of zinc include red meat, sea food and unprocessed cereals 
and nuts, but Brown et al (Brown 1982) demonstrated that 50% of Bangladeshi
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children had never received meat, fish or eggs by 30 months age. In this group all 
children between 5 and 12 months of age and 85% of children between 24 and 30 
months were breast-fed; the average amount of breast milk received by these age 
groups declined from 632 to 368 g/day. Concurrently, the rate of consumption of 
cereals increased from 54 to 100% of children, and the amount received increased 
from 35 to 94 g/day. Breast milk was the major source of all nutrients for younger 
children.
The zinc content of the rehabilitation diets used in this study was very difficult to 
measure accurately. The children were initially fed on liquid diets via nasogastric 
tubes and both the dried skimmed milk and rice based liquid diet had some 3mg zinc 
per 1000ml of feed. However, as soon as their appetite had returned these children 
were then encouraged to eat solid food ad libitum. These foodstuffs were of local 
origin and, as one of the important health education messages to the mothers was that 
they could provide a healthy diet to their children, it was important that local mixtures 
of food such as khichuri and curries were included. Whilst every effort was made to 
standardise the contents of these solid food mixes it was recognised that both the zinc 
content and the individual estimates of food ingested were inaccurate.
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4.1. Anthropometry
This population of severely malnourished children was both severely wasted and very 
severely stunted with a mean initial WHZ of -2.66 and HAZ of -3.89 respectively.
This would indicate both an underlying long-term deficit in growth and nutrition 
(manifest in HAZ scores) and an acute nutritional insult (manifest in WHZ score). In 
this study of catch-up growth during recovery from severe protein-energy 
malnutrition, neither higher dose nor longer duration zinc supplementation regimens 
had any appreciable anthropometric benefit over the lower dose regimen across the 90 
days of the study. On average good ponderal and linear catch-up growth was achieved 
within all three groups with a wide intragroup variation but no significant intergroup 
differences. The majority of ponderal growth and practically all of the linear growth 
occurred during the out-patient phase of the trial when the subjects had returned to the 
environment in which they had originally become deficient in protein, energy, zinc 
and presumably other micro-nutrients. Neither the employment of higher zinc dosages 
for the in-patient period (regimen 2) nor prolonging the period of supplementation to 
day 30 of the out-patient phase (regimen 3) had a significant effect in promoting 
further growth. As the confidence limits in table 10 show, any benefit was unlikely to 
average more than 0.2 - 0.5 units of the three Z scores.
The effect of a single micronutrient supplement to severely malnourished children 
undergoing refeeding might be expected to be overwhelmed by the beneficial effect of 
full nutritional rehabilitation. However when sufficiency of that micronutrient limits 
macronutrient utilisation e.g. zinc, then this experimental design has been effective 
(Castillo-Duran 1987; Simmer 1988). In the absence of a control group with no zinc 
supplementation it is difficult to discern whether zinc had no effect in this instance or
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rather that that the regimens had no significant difference in effect. On review of the 
study in Bangladesh it was concluded that there was enough evidence to suggest that 
severely malnourished children benefited from zinc supplementation and that 
comparing the effects of different zinc regimens against placebo would be unethical.
During the initial phase of rehabilitation zinc is required for growth, particularly lean 
tissue deposition, and also for recovery of immune function. The process of 
replenishing both lean tissue and hepatic pools and allowing for optimal functioning 
of the immune system provides for an environment in which growth can continue 
after zinc supplementation has stopped. One of the major tenets of nutritional 
rehabilitation is the promotion of healthy weaning diets and health education was 
central to management of these children. The success of this is witnessed by the fact 
that most of these children continued to thrive after discharge into the same 
environments in which they initially became malnourished. Dietary variety was a key 
theme in the advice offered and it may well be that as a result of this that zinc intakes 
increased. Continuing the higher dosage zinc supplementation into the outpatient 
phase of rehabilitation did not have any anthropometric benefits.
Ponderal growth was not significantly influenced by supplementation regimen. 
Severity of initial wasting was significantly negatively correlated with subsequent 
change in WHZ score and inpatient weight gain was significantly positively 
correlated with subsequent change over both 45 and 90 days. As individual children 
approached their median WHZ score rate of weight gain slowed.
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Linear growth was not significantly influenced by regimen and largely took place in 
the second half of the study after weight gain was first achieved. However it occurred 
even in the presence of severe wasting. Linear growth was significantly positively 
correlated with initial degree of wasting and inpatient change in height for age z score 
over both 45 and 90 days but not with inpatient change in weight for height z score 
even in those children without nutritional oedema. 0.5 z score linear catch up was 
demonstrated over 90 days 50% of which took place in the last 30 days of the study. 
Walker et al detailed early linear growth in 369 recovering malnourished children in 
Jamaica. Only a more stunted subgroup (n=108 and mean HAZ -4.3) demonstrated 
linear catch up growth and two thirds of these attained at least 85% weight for length 
before they began to increase in length (Walker 1988). In this study linear growth 
occurred even in severely wasted children with no threshold identified. With 
increased wasting growth was predominately ponderal and linear growth only 
approached ponderal when initial WHZ score was 1 z score below median. Linear and 
ponderal growth do occur concurrently with initial WHZ score determining whichever 
predominates. Whether interventions designed to promote linear growth act via 
improving ponderal growth to that point where linear growth predominates or allow 
for linear growth at a lower initial WHZ score is not clear. The switch to skeletal 
growth, lean tissue deposition and linear growth is not understood but as zinc 
supplementation promotes lean tissue deposition it thus has been postulated to 
preferentially promote linear growth.
Identifying predictors of linear growth in these children is difficult. If we use in­
patient change in HAZ to predict for linear growth over 90 days it must be 
appreciated that this is not an independent variable. Change in WHZ score preceding
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linear growth has previously been described as a predictor (Walker 1996) but did not 
predict in our model. Initial WHZ score and maternal height did predict but only 
accounted for 20% of total variance.
Inpatient ponderal growth predicts well for ponderal growth over the subsequent three 
months and those children who demonstrated most linear catch-up growth were those 
who were least malnourished initially and those that demonstrated most linear growth 
as an inpatient.
Knemometry has been used in well nourished children as an index of linear growth, 
but the relationship between total linear growth and knemometric growth is not clear 
as different parts of the skeleton appear to grow at different rates and times. In our 
group knemometric growth did not correlate with linear growth until after day 45 of 
the study. Across all time periods knemometric growth correlated positively with 
change in mid-upper arm circumference, triceps skinfold thickness and weight for 
height z score. The knemometric measurements behaved more as an index of ponderal 
growth than of linear growth in this group particularly in the first 45 days. As well as 
measuring changes in the length of the tibia and fibula the knemometer also measures 
changes in the soft tissues overlying these and the deposition of fat in the supra­
patellar and heel fat pads as well as changes in tissue oedema contributed to 
measurements. Knemometry offers an accurate and reproducible index of lower leg 
growth and was hoped to be a useful index of linear growth with the potential benefit 
of allowing shorter follow-up periods to demonstrate differences between groups. 
However in this group of children this application is limited.
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In summary I concluded that there was no anthropometric benefit in employing the 
higher dosage zinc supplementation regimens nor prolonging supplementation into 
the outpatient phase. Linear growth may occur even in the presence of severe wasting 
but is strongly correlated with initial weight for height z score. The knemometer is of 
limited use as an index of linear growth in this group of children.
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4.2. Mortality
The most striking finding of this study was the increase in mortality associated with 
initial exposure to the higher dosage zinc regimens (6.0mg/kg/day) as opposed to the 
lower dosage zinc regimen (1.5mg/kg/day). The inpatient death rate among those 
recruited to the higher dose zinc regimens was 12% (over 3 months 19%) whilst that 
for the lower dose zinc group was 4% (over 3 months 4%) - this compared with the 
unit inpatient death rate of 18% just before starting the trial. This could indeed be a 
chance finding, but the plausibility of this being a true association must be considered.
Most of these deaths were sepsis-related and occurred during the inpatient phase of 
rehabilitation, and therefore the effect of supplemental zinc on the immune system of 
the malnourished child must be considered. Malnourished children are commonly 
zinc deficient (as evidenced by subsequent response to supplemental zinc). The 
evidence for this in Bangladesh is particularly strong (Khanum 1988; Simmer 1988). 
Previous supplementation trials in children recovering from severe protein energy 
malnutrition have demonstrated significant benefits and dietary zinc deficiency is well 
described here (Simmer 1990). Zinc is now routinely supplemented on many 
nutritional rehabilitation units in Bangladesh.
Zinc plays a central role in the immune system and deficiency affects immune 
function at multiple levels in both the innate and specific arms. GI barrier function, 
polymorphonuclear and natural killer function and complement activity are all 
affected (Shankar 1998; Allen 1983; Montgomery 1979). Cell mediatedimmunity is 
profoundly affected in zinc deficiency. Lymphopenia is common as are defects in 
specific T and B lymphocyte function (Pekarek 1979; Chandra 1980; Fraker 1982;
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Beisel 1982). Secretion and function of cytokines (Beck 1997) and the potentiation of 
apoptosis (Elmes 1977) are also affected by zinc deficiency. Zinc may have a role in 
prevention of free-radical induced injury mediated through its antioxidant (Bray 1990) 
and cell membrane stabilising properties. Lymphoid atrophy, decreased delayed 
cutaeneous hypersensitivity responses, reduction in numbers of T4 helper cells and 
deficient thymic hormone activity have been described in association with zinc 
deficiency. B cell dysfunction, and specifically impairment of phagocytosis, has also 
been described.
Zinc supplementation of malnourished children improves immune function. Initial 
observations included enlargement of thymic shadows in marasmic children given 
lOdays of zinc supplementation (Golden 1977). Marasmic children (mean age and 
weight for age were 7 months and -3.1 z scores) given 2mg/kg/d supplemental zinc 
for 105 days had significantly improved linear growth, significantly increased 
conversion of delayed hypersensitivity skin reactions and enhanced 
lymphoproliferative response to phytohaemagglutin (PHA) and increased salivary IgA 
concentrations compared to non-supplemented infants (Schlesinger 1992). Twenty- 
five undernourished (mean age and WAZ: 42 mth and -1.4) Ecuadorian children 
randomised to lOmg/day of zinc for 60 days had significantly larger delayed type 
hypersensitivity skin reactions than controls. They also had a significantly decreased 
incidence of fever, cough and upper respiratory tract secretions during 
supplementation that disappeared on stopping the supplementation in the second half 
of follow-up (Sempertegui 1996). Sixteen undernourished Chilean infants (mean age 
and weight for age: 7mths and 67% of median) given 2mg/kg zinc per day for 90 days
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demonstrated significantly better weight gain serum IgA and significantly reduced 
incidence of pyoderma and percentage of anergy (CastilloDuran 1987).
However, zinc supplementation in the presence of ongoing sepsis and an already 
compromised immune system may not necessarily be beneficial. Zinc, in 
physiological range, has been associated with impairment of granulocyte phagocytosis 
(Mustafa 1971; Stankova 1997; Chavpil 1977). In animal experiments supplemental 
zinc increased serum levels and was associated with decreased mobilisation of 
polymorphonuclear cells and macrophages into the peritoneal cavity and phagocytosis 
(Chavpil 1976). 150mg of elemental zinc twice a week for six weeks given to eleven 
healthy adult men was associated with a reduction in lymphocyte stimulation response 
to phytohemmagglutin as well as chemotaxis and phagocytosis of bacteria by 
polymorphonuclear leukocytes (Chandra1984). Marasmic infants fed a zinc fortified 
liquid diet (15mg zinc/1) demonstrated reduced phagocytic and fungicidal monocytic 
activity and a significantly increased number and duration of impetigo episodes 
(Schlesinger 1993).
Serum levels of zinc decrease sharply in inflammation and infection and may reflect a 
natural protective mechanism, as lower levels of zinc are associated with both optimal 
phagocytic function and decreased microbial virulence (Sugarman 1983). This 
decrease is accounted for largely by a redistribution to the liver (Powanda 1973; 
Pekarek 1972) serving to favor the immune system in the production of acute phase 
proteins and haemopoesis (Chavpil 1976). Optimal phagocytosis of latex particles 
correlates with slightly decreased levels of zinc in human serum and 
polymorphonuclear cells (Lennard 1974). Calprotectin, an acute-phase zinc binding
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protein may play a role in reducing extracellular zinc concentrations in inflammation 
(Clohessy 1995). Zinc is important in microbial virulence with near physiologic 
concentrations of zinc necessary for toxin production in Clostridium perfringens 
(Murata 1969) and Pseudomonas aeruginosa (Jensen 1980) and in the adherence of 
Enterobacter to epithelial surfaces (Sugarman 1980).
Serum iron levels also fall during infection as a result again of redistribution to the 
liver, reticuloendothelial system and bone marrow. Early iron supplementation of 
children with severe protein energy malnutrition led to increased mortality (Smith 
1989) probably due to increased microbial virulence and free radical generation.
In our study the length of time between admission and recruitment was between 2.5 
and 3.5 days and reflected the units policy on early commencement of incremental 
feeding regimens and micronutrient supplementation. This reflects both the intense 
social pressures on mothers to leave hospital as quickly as possible and a general 
move away from in-patient to out-patient based rehabilitation. However since most 
children presented to the unit with intercurrent infections, it is unlikely that by three 
days all children were free of infection. In previous trials of zinc supplementation in 
severely malnourished children, the zinc supplement was administered at a later stage 
of rehabilitation when it was much less likely that sepsis was ongoing - a situation 
unlikely to be representative of practice in most nutritional rehabilitation units.
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4.3. Zinc and copper
As well as having a possible directly detrimental effect on the immune system during 
sepsis, high dose zinc supplementation could aggravate deficiencies of other minerals 
by decreasing their intestinal absorption. Zinc inhibits copper absorption and copper 
deficiency can co-exist with severe protein-energy malnutrition (Cordano 1964; 
Hemalatha 1993). Copper deficiency is also associated with an impaired immune 
response, specifically a reduction in the antibody response to T cell dependent 
antigens and a decrease in the microbiocidal activity of phagocytes (Vyas 1983; Babu 
1989). Metallothionen, an intracellular polypeptide, plays an important regulatory role 
in the metabolism of ingested zinc and copper. It binds copper more avidly than zinc. 
Zinc induces the synthesis of metallothionen (Yuzbasiyan-Gurkan 1992) thus 
preventing serosal transfer to blood of ingested copper as well as endogenously 
secreted copper in GI, salivary and pancreatic juices. Zinc in large doses can therefore 
produce chronic negative copper balance particularly in the presence of a pre-existing 
copper deficiency. Zinc induced copper deficiency has been documented (Botash 
1992; Sandstrom 1994; Honkanen 1991; Porter 1977; Prasad 1978) though very high 
levels of zinc for prolonged periods are usually required to manifest it. Prasad (Prasad 
1978) describes how 150 mg of Zn per day for 23 months precipitated severe copper 
deficiency in patients with sickle cell disease and Porter (Porter 1977) describes how 
the same level of zinc supplementation for 13 months again precipitated copper 
deficiency. However an intake of 18.5mg of zinc per day for just two weeks reduced 
apparent copper retention in a group of healthy well nourished men (Festa 1985). In 
23 previous zinc supplementation studies using 1 to 10 mg/kg/day for two weeks to 
1.25 years, no side-effects related to copper status were reported
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Seven of these studies (2 to 6 mg/kg/day given for 21 days to 1.25 years) examined 
biochemical markers of copper status and none showed an effect as measured 
variously by serum/plasma copper and caeruloplasmin levels or superoxide dismutase 
activity.
Table 23: Zinc studies -  effects on copper status
Investigator Year Copper status assessment and effect
Bates CJ 1993 Y (hair copper and superoxide dismutase levels) -  no 
effect
Behrens RH 1990 N
Castillo-Duran C 1987 Y (plasma copper) - no effect
Gibson RS 1989 Y (plasma & hair copper, and caeruloplasmin)- no 
effect
Golden BE 1981 N
Golden MHN 1981 N
Halstead JA 1972 N
Hambridge KM 1985 N
Hemalatha P 1992 Y (plasma copper) -  no effect
Krebs NF 1994 N
Ronaghy HA 1974 N
Sachdev HPS 1988 N
Sella GE 1991 N
Simmer K 1988 N
Walravens PA 1989 N
Walravens PA 1983 Y (plasma copper) -  no effect
Cavan KR 1993 N
Nakamura T 1993 N
Shrivastava SP 1993 N
Schlesinger L 1992 Y (plasma copper) -  no effect
Walravens PA 1976 Y (plasma copper) -  no effect
Khanum 1988 N
Sempertegui 1996 N
Severely malnourished children are immunocompromised and frequently present to 
hospital with intercurrent infections. Infection in these children is often difficult to 
recognise, tends to be aggressive and disseminates easily. Broad-spectrum anti­
microbials are now advocated for all children that present with severe malnutrition
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(Schofield 1996). C reactive protein (CRP) concentrations increase with the acute 
inflammatory response even in the presence of severe malnutrition (Manary 1998; 
Sauerwein 1997) and are a useful clinical tool in detecting sepsis. Day 1 mean 
regimen plasma CRP concentrations were between 12 and 19mg/l and between 34 and 
37% of values were abnormal with no significant inter-regimen differences. At the 
end of the inpatient period (day 15) the mean regimen CRP concentration had 
dropped to between 2 and 10mg/l with no difference between regimens but with a 
significant increase in numbers of children with an abnormal CRP concentration in 
the high (regimens 2&3) as compared to the low dosage (1) regimen. Thus the 
prevalence of inflammation was equally distributed on admission but by day 15 those 
children that had received the higher dosage zinc supplement had an increased 
prevalence. At day 30 there were no significant inter-regimen differences in mean 
CRP concentrations or absolute numbers of children with abnormal CRP 
concentrations. Rehabilitation was established, children had gone home and most 
deaths had occurred making analysis of the survivor CRP concentrations difficult to 
interpret. However it might suggest that this proposed immunosuppressive effect was 
maximal on admission and thus have implications for the timing of zinc 
supplementation in these children. Abnormal CRP’s were found in 12% of children at 
day 30 re-enforcing the need for close follow-up as the recovery period for immune 
function of these children has not been defined.
Those children who died had significantly elevated day 1 mean CRP concentrations 
compared to survivors and there is a significant association between death and an 
abnormal CRP. This supported the clinical impression of sepsis as cause of mortality.
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Plasma zinc and copper concentrations were measured in these children on days 1,15, 
and 30. Plasma zinc concentration increased with supplementation and was 
significantly higher in the high dosage regimens compared with the lower. Day 30 
plasma zinc was significantly higher in those that received supplementation onto day 
30. Plasma copper concentration increased throughout the study period and did not 
differ between regimens. Though inflammation affects plasma copper concentrations 
a regression analysis of day 15 copper, zinc and CRP concentrations demonstrated 
that inflammation did not confound the relationship between regimen and plasma 
copper concentration. There is therefore no evidence that a copper deficiency 
developed in those children who received the higher dose zinc supplement
In conclusion, neither the use of a higher dosage of zinc initially nor prolonging the 
period of supplementation resulted in a significant anthropometric benefit among 
severely malnourished children, and indeed, using the higher dosage was associated 
with increased mortality. It is recommended therefore that caution should be 
employed in its use. Further studies are needed to define the relationship between zinc 
and the immune response, how best to assess zinc status, what is the optimal level of 
zinc supplementation and when is it best to administer it.
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4.4. Collagen turnover and IGF axis activity
In this study plasma IGF-I, IGFBP-3, PICP and P3NP (markers of bone and soft 
tissue collagen synthesis respectively), and BAP were low and increased within 15 
days (P <0.001). IGFBP-2 and ICTP (a marker of type I collagen degradation) were 
increased and fell during refeeding (P <0.001). There were no differences in 
biochemical marker responses among the zinc regimens. IGFBP2 correlated 
positively with ICTP and negatively with PICP, BAP, IGF1 and IGFBP3 (p<0.01). 
Ponderal growth correlated with increases in IGF-I, IGFBP-3, PICP, P3NP and BAP 
over 30 days (P <0.01). Linear growth over 90 days correlated with increases of 
IGFBP-3 (P<0.05), PICP (P <0.01) and P3NP (P <0.01) over 30 days.
Linear growth is dependent on skeletal growth, which occurs when osteoblastic bone 
formation predominates over osteoclastic bone resorption. Bone is continually 
remodelled and longitudinal bone growth during childhood is dependent on GH 
(Nilsson 1994). Control of resorption and formation is complex with evidence 
pointing to the components of the GH/IGF axis as providing the complexity required 
to selectively regulate complementary processes to suit demands. IGF’s regulated 
osteoblast and osteoclast proliferation and collagen synthesis in vitro (Rosen 1994) 
and recombinant IGF1 stimulated bone formation in women (Johansson 1992). 
Locally produced IGF’s acting as autocrine or paracrine agents have been postulated 
as mediating in the coupling of bone formation to resorption (Hayden 1995; Chihara 
1997).
IGF1 is produced both in the liver and locally in multiple cell types in response to GH 
to promote cell growth. IGFBP’s transport IGF’s, control tissue specific availability,
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regulate clearance, modulate receptor interaction with the IGF’s and have a direct 
effect on cells (Clemmons 1998). Malnutrition is associated with GH resistance (high 
GH and low IGF 1 levels) which may represent an adaptive mechanism to promote 
lipolysis and fatty acid oxidation whilst attenuating the anabolic actions of GH on 
protein synthesis (Soliman 1986). Animal studies demonstrated reduced GH binding 
capacity, post GH receptor defects, reduced IGF1 gene transcription and translation in 
fasting or protein restriction as well as increased IGF1 clearance (Thissen 1991; 
Thissen 1990; Maes 1988). IGF1 levels in children declined in response to 6 days of 
protein or energy restriction with an associated increase in IGFBP2 in protein 
restriction only (Smith 1995). Levels of IGFBP3, the principal carrier of IGF 1, are 
more consistently reduced by prolonged malnutrition along with IGF1. (Ketelslegers 
1996). A 3 day fast in obese and non-obese subjects with non-insulin dependant 
diabetes did not alter IGFBP3 (Bang 1994) whereas in anorexia nervosa it is 
significantly decreased together with IGF1 and IGFBP2 was markedly elevated 
(Counts 1992). Increase in IGF1 levels correlated temporally with entry into positive 
nitrogen balance in 6 malnourished adults who were receiving nutritional support and 
proved a more sensitive index of acute directional changes in nutritional status than 
other plasma proteins (Clemmons 1985). When malnourished Bangladeshi children 
recovering from Shigellosis were fed either a normal protein (6% of total dietary 
energy) or high protein diet (12%), better weight gain, higher IGF1 levels and a larger 
decrease in IGFBP2 levels were noted in the high protein group (Pucilowska 1993).
Micro as well as macronutrients influence catch-up growth in malnourished 
children. lOmg of zinc per day for 5 months produced significant increases in weight 
and height and significant reductions in infectious morbidity in stunted Vietnamese
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children associated with a significant increase in IGF1 levels. Between 1 and 5 
months post supplementation IGF1 concentration increased from a mean of 2.8 to 3.4 
nmol/1 with no increase in the placebo group suggesting that zinc deficiency was 
limiting growth in these children and that zinc stimulated growth through changes in 
circulating IGF 1 (Nguyen 1996). 220 prepubertal stunted Japanese children were 
randomised to receive either 2mg/kg zinc per day for 6 months or placebo. The zinc 
supplemented group had significantly increased energy intakes, growth velocity and 
insulin like growth factor 1 levels but urinary excretion of growth hormone was 
unchanged as were plasma levels of other pituitary hormones. This might indicate that 
zinc has a role in binding GH to its receptor in hepatic cells (Nakamura 1993). Zinc 
depletion in rats resulted in reduced body weight gain, serum IGF1 concentration, 
hepatic growth hormone receptors and serum growth hormone binding protein levels 
(GHBP). Liver IGF1 mRNA levels were reduced by zinc deficiency suggesting that 
the decline in IGF1 levels was mediated through decreased hepatic GH receptors 
and/or GHBP levels (Ninh 1995). Exogenous GH failed to stimulate growth and raise 
IGF1 in zinc deficient rats suggesting GH resistance as a result of a decrease in liver 
GH binding sites and/or a decrease in GHBP (Prasad 1969).
I demonstrated both initial low levels of IGF 1 and IGFBP3 which increase 
significantly with rehabilitation and high initial levels of IGFBP2 which subsequently 
fall. Metabolic adaptation to malnutrition requires a reduction in protein synthesis 
whilst rehabilitation and catch-up growth demand both lean tissue deposition and 
bone growth. Changes in both local and circulating levels of IGF’s and their binding 
proteins may regulate this switch. The positive correlation between IGFBP2 and 
ICTP and negative correlations with PICP, IGF1 and IGFBP3 support a role for
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dietary protein sensitive IGFBP2 regulating bone formation/resorption coupling 
directly or through availability of IGF’s.
There were no differences in growth between the 3 zinc regimens and no differences 
in change of IGF 1, the binding proteins or any marker of collagen or bone turnover 
(except for D30 BAP). In the absence of a control group with no zinc supplementation 
(deemed unethical) it is impossible to further comment on the role of zinc in the 
catch-up growth of these children. Both type 1 and type 3 collagen formation and 
bone osteoblastic activity increased significantly early in rehabilitation and change in 
these markers was significantly positively correlated with change in IGF1 and 
IGFBP3 over the same period. Type 3 collagen formation increases more relative to 
European children in the first 30 days of rehabilitation than type 1. Growth is 
predominately ponderal in this early phase of rehabilitation reflected in early 
improvement in WHZ but not HAZ scores. Change in PICP, P3NP, BAP, IGF1 and 
IGFBP3 all correlated with weight gain over the same period. Change in collagen 
formation markers and IGF1 levels over 30 days also correlated with ponderal growth 
over 90 days but less well.
The most significant predictor of linear growth in these children that we were able to 
identify was their weight for height z scores at presentation. Most linear growth 
occurred in the later stages of the 3 month follow-up associated with significant 
ponderal growth. Knemometry behaved as a ponderal index acutely in this group of 
children reflecting soft tissue deposition as well as bone growth and only after 45 days 
correlated with linear growth. Change in collagen formation correlated with the small 
amount of linear growth over the first 30 days and this correlation improved with
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linear growth over 90 days. Change in lower leg length over the first 30 days 
correlated significantly with change in both type 1 bone predominate collagen, type 3 
soft tissue collagen, BAP and IGF1 as did change in WHZ score. Improved 
correlations with change in PICP and P3NP were associated with lower leg growth 
over 90 days that correlated in addition with change in IGFBP3 (as did change in 
HAZ) and change in BAP.
Collagen degradation was assessed both by urinary levels of pyridinium crosslinks 
and plasma levels of cross-linked telopeptide of type 1 collagen. ICTP fell with 
rehabilitation and correlated negatively with type 1 collagen formation (PICP), IGF1 
and IGFBP3 and positively with IGFBP2 levels. Conversely PYD and DPD levels 
increased and did not correlate with type 1 collagen formation markers or growth 
factor activity. PYD and DPD were measured in spot urine samples and expressed 
them as a ratio to creatinine excretion which may well change dramatically in the 
malnourished catabolic child who becomes anabolic (Branca 1992). ICTP is a plasma 
marker and not subject to changes in creatinine production and excretion.
Marasmus and kwashiorkor occupy opposite ends of the clinical spectrum of severe 
malnutrition and may represent both different types of and responses to nutritional 
insults. The children with kwashiorkor in our study had significantly better initial 
HAZ scores than the marasmic children indicating that the chronic nutritional insult 
underlying their acute nutritional deficit (manifest in WHZ score) was less severe in 
nature. Similarly aged marasmic Gabonese children demonstrated low initial IGF1 
and IGFBP3 levels with increased IGFBP3 proteolytic activity which normalised after 
4 weeks of rehabilitation. Gabonese children with kwashiorkor however initially had
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low IGF1 and normal IGFBP3 levels with low IGFBP3 proteolytic activity and after 
rehabilitation IGFBP3 levels fell and proteolytic activity increased (Zamboni 1996). 
This was proposed as an aflatoxin mediated effect however when comparing 
Bangladeshi and Gabonese children with kwashiorkor the difference in initial HAZ 
scores and thus the chronicity of the nutritional insult was impressive ( -2.9 vs -0.34). 
Severe prolonged nutritional insults cause greater deficits in HAZ scores as well as 
IGFBP3 levels and difference in IGFBP3 levels between children with marasmus and 
kwashiorkor disappeared when differences in initial HAZ score were controlled for. 
Linear catch-up growth also correlated significantly and positively with change in 
IGFBP3 levels.
In conclusion, bone remodelling and soft tissue turnover commence early in the 
nutritional rehabilitation of severely malnourished children and did not differ between 
the 3 zinc regimens. This switch to collagen deposition and bone growth is associated 
with a fall in IGFBP2 and an increase in IGF1 and IGFBP3. Alterations in GH/IGF 
axis local mediators in response to diet may control the coupling of bone resorption to 
formation and collagen deposition in these children.
Bone remodelling and soft tissue turnover is complex and the measurement of a 
number of biochemical variables representative of different processes is required to 
understand this complexity. The combination of assays employed here to document 
collagen deposition, degradation, and IGF axis changes offer a comprehensive 
toolbox to allow the identification and assessment of individual processes that 
combine to produce growth. Nutritional interventions to produce growth (usually 
combining micronutrients and macronutrients) act at many levels and it is often
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unclear to what extent ponderal and linear components contribute overall, to what 
extent individual processes contribute either to ponderal or linear growth and what 
micronutrient/macronutrient components of an intervention specifically do. 
Measurement of the individual components of growth and the use of a toolbox of 
assays of collagen turnover, bone growth and IGF axis activity may allow a more 
detailed understanding of the effects of interventions and the optimisation of such 
interventions to produce optimal patterns of growth. Complex toolboxes produce 
complex results however and further studies are needed to test the utility of such an 
approach.
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Clinical Implications
The correct micronutrient/macronutrient mix to enable severely malnourished 
children to realise their full growth potential remains unclear. Much progress has been 
made in optimising regimens and the current WHO guidelines represent best practice 
as currently understood. Zinc supplementation is known to be an essential component 
of this. This study demonstrates that the use of high dose or prolonged zinc 
supplementation did not produce significant additional benefit and that the use of high 
dose supplementation was associated with increased mortality.
Zinc supplementation of deficient children improves immune function and there is no 
evidence that zinc supplements cause harm when given to non-septic 
immunocompetent children. In the septic severely malnourished child however the 
immune response to supplementation is less predictable and competing microbes may 
benefit before the severely compromised immune system can use the supplement to 
recover. The dose of supplement employed here may well have tipped the balance of 
benefit in favour of the pathogen and away from the malnourished child.
It must be emphasised that all the organs/organ systems of severely malnourished 
children are compromised and that the immune system is as damaged as, for example, 
the gastrointestinal system. This accounts for the largest proportion of early mortality 
during rehabilitation of these children and underlies the WHO's recommendations 
that all such children should receive empiric broad-spectrum antibiotic coverage on 
admission. Nutritional interventions in this group of children must recognise this and 
the macronutrient/micronutrient mix that is most beneficial for well malnourished
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children is not necessarily what is best for septic malnourished children -  this has 
already been demonstrated with iron supplementation of these children.
Until the optimal macronutrient/micronutrient combination is better defined high dose 
zinc supplementation of severely malnourished children should be avoided.
Future Research
The research documented in this thesis has raised more questions than it has 
answered. Particular areas and questions have been highlighted as requiring further 
research and illustrate the need for more ‘mechanistic* studies on the effects of 
supplementation.
Zinc
- a biochemical index of zinc sufficiency unaffected by the presence of inflammation 
is required to define the zinc status of individuals on entry into supplementation trials.
- a better understanding of the mechanisms and control of zinc flux and storage, and 
the contribution of host genetic heterogeneity is required to predict results of 
supplementation
- the effects of inflammation and ongoing sepsis on the response to micronutrient 
supplementation and whether optimal micronutrient/macronutrient combinations 
depend on the presence/absence of ongoing sepsis
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Growth of severely malnourished children
- The determinants of linear catch-up growth of severely malnourished children 
remain to be determined -  we could only identify factors that accounted for 20% of 
variance in this study. Whether these determinants are amenable to intervention also 
needs to be answered.
- The effects of micronutrient/macronutrient supplementation and interaction on the 
composition of newly laid down tissue, bone growth, GH-IGF axis activity and the 
promotion of linear as opposed to ponderal growth requires further research.
- We need to understand better what represents optimal ponderal and linear growth of 
severely malnourished children and to know how aggressive should we be in 
promoting it.
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Appendix 1: Sample size calculation
With 90% power at the 5% level, the following approximate sample sizes would be 
required (formula n = 10.5 (SDj2 + SD2^ ) / where SDj and SD2 are the 
standard deviations and D is the difference in the outcome measure.
i) Bisgaard et al showed the SD of normal lower leg length in this age group to 
be 153 pm / day, and the daily leg length growth using weekly measurements to be 92 
pm / day. Using these figures in the above formula, to show a difference between the 
groups of 92 pm / day increase in lower leg length, n = 29. The accuracy of 
measurements with the portable knemometer is approximately 50 pm / day.
ii) Kabir et al showed a difference in change of height for age Z-score of 0.09 
between groups fed normal protein or high protein diet in malnutrition refeeding. 
Standard deviations of the two groups were 0.04 and 0.12. Using these figures, in 
order to show a difference of 0.09 in change of height for age Z-score between the 
two intervention groups, n = 21.
iii) Kabir et al showed a difference in change of weight for age Z-score over 21
days of 0.23 between groups fed normal protein or high protein diet in malnutrition
refeeding. Standard deviations of the two groups were 0.27 and 0.38. Using these 
figures, in order to show a difference of 0.23 in change of weight for age Z-score 
between groups, n = 43.
iv) Kabir et al showed a difference in change of weight for height Z-score over 
21 days of 0.25 between groups fed normal protein or high protein diet in malnutrition 
refeeding. Standard deviations of the two groups were 0.3 and 0.4. Using these
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figures, in order to show a difference in weight for height Z-score of 0.2 between 
groups, n = 50.
v) Skin fold thickness and mid upper arm circumference - data for calculation of 
sample size not available.
vi) Kabir et al showed a difference of 23.4 nmol /1 in change of IGF 1 following 
refeeding malnourished children with normal protein vs high protein diet. Standard 
deviations in the two groups were 16.2 nmol /1 and 9.2 nmol /1. Using these figures, 
in order to show a difference of 23.4 nmol /1 in change of IGF 1 between groups, n = 
7.
vii) IGFBP3 - no data available for sample size calculations.
viii) Trivedi et al showed a difference in PICP levels of 130 pg /1 between 
children with average height velocity of 2.18 cm / y and 6.02 cm / y. Standard 
deviations in the two groups were approximately 250 pg /1. Using these data, in 
order to show a difference of 130 pg /1 in change of PICP between groups, n = 39.
ix) Trivedi et al showed a difference in P3NP level of 2.1 pg /1 between children 
with average height velocity of 2.18 cm / y and 6.02 cm / y. Standard deviations in 
the two groups were approximately 4.125 pg /1. Using these data, in order to show a 
difference of 2.1 pg /1 in change of P3NP between groups, n = 41.
x) Branca et al showed a difference in PYD of 21 nmol / h / vcfi between 
malnourished and recovered children. Standard deviations of the two groups were 4.6
nmol / h / m^ and 10.8 nmol / h / nfi. Using these data, in order to show a difference
of 5 nmol / h / nfi in change of PYD between groups, n = 58.
xi) Branca et al showed a difference of 4.9 nmol / h / m^ in DPD between 
malnourished and recovered children. Standard deviations of the two groups were 1.3
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nmol / h / and 3.0 nmol / h / nA  Using these figures, in order to show a 
difference of 2.5 nmol / h / nA n change of DPD, n = 18.
Taking the largest anthropometric outcome of these sample size calculations, the total 
sample size would need to be 150. Allowing for 20% drop out, if we recruit 180 
subjects complete data should be available on 150 subjects. Stratified randomisation 
should ensure that other confounding variables are equally represented although 
collection of data on possible confounders should enable these variables to be 
controlled for in a multiple regression analysis if necessary.
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Appendix 2: liquid diets
1. Rice Powder formula
60gm of rice powder 
40ml of soya oil 
75gm of egg albumin
Water up to 1000ml
- 2590 kJ energy 
-11 gm protein
- 3 mg zinc
2. Dried Skimmed Milk Formula
80gm of dried skimmed milk 
65 gm of sugar 
49ml of oil
Water up to 1000ml
- 2640 kJ energy
- 22 gm protein
- 3 mg zinc
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Appendix 3: Zinc and placebo formulations
Zinc as zinc sulphate (ZnSC>4) in 200mg tablets. 
200mg ZnSo4 tablet equivalent to 81.46 mg zinc.
Formula 1 Formula 2 Formula 3
ZnSC>4 44gm 352gm /
Sugar 5.81kg 11.63kg 5.81kg
Citric acid 2.91gm 5.81gm 2.91gm
Na Benzoate 11 -63g 23.26gm 11.63gm
Aroma orange 11.63gm 23.26gm 11.63gm
Distilled water to 11.63 litres 23.26 litres 11.63 litres
Elemental Zn/ml 3.75 15 /
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Appendix 4: Consent form
Consent form Name of Patient
Your child has been admitted to this unit because he/she is malnourished. He/she 
needs to be carefully fed for two weeks or more to make him/her better. We are doing 
a study to help to find out what is best for a child to be fed at this important time, and 
how this might make him/her grow.
In the study, we will give some children a multivitamin syrup containing a certain 
dose of zinc, and others a multivitamin syrup with a smaller dose of zinc. Which 
children get what dose of zinc will be decided by chance. We will then see you 
during the admission here, and afterwards in the clinic every 2 weeks for 3 months, to 
measure your child. Some people have shown that zinc may improve the way a child 
grows, while others have not shown this. Zinc does not harm your child. By 
comparing the growth of children in the two groups, we hope to show whether or not 
zinc helps.
We also want to look at how children grow after being sick. To do this we need to do 
three blood tests over a 1 month period. These blood tests involve one prick with a 
needle each, and a small amount of blood being taken for some tests to be done in the 
laboratory. The blood is taken from a vein, and each time we will take about 1 
teaspoon-full (5ml). The tests will give us important information about how the zinc 
might work. We can give you more information about these tests if you want.
The study involves no risk to your child. There will be some minor, temporary 
discomfort due to the blood tests.
If you agree, we will include your child in the study. If you do not agree, then your 
child will still get all the normal treatment on the unit. If you agree now, but later 
change your mind, then you can remove your child from the study immediately 
without affecting his/her further treatment in this unit.
If you are happy for your child to be included in the study, please give your consent 
by signing this form. If you have any questions about the study please ask.
Parent's / guardian’s signature / left thumb print
Prof Akbar’s signature Dr Conor Doherty’s signature
Dr Kaseem Sarkar’s signature Dr Saleem Shakur’s signature
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